

DESCRIPTION

Carbohydrate Library Constructed by Gene Alteration of Cargo Receptors

5 TECHNICAL FIELD

The present invention relates to a method for modifying a carbohydrate moiety of a glycoprotein and for preparing a glycoprotein having a modified carbohydrate moiety. The present invention further relates to a cell expressing a glycoprotein having a modified carbohydrate moiety and a method for preparing
10 the cell. The present invention further relates to a method for producing a glycoprotein having a modified carbohydrate moiety.

BACKGROUND ART

Today the entire nucleotide sequences of the human genome is being
15 elucidated and tailor-made medical treatment is going to begin based on the large amounts of such information. A new era is coming where diagnosis methods for extensively examining protein expression using DNA chips and prescription of drugs based on the data can be carried out via computers. In addition, it is also considered that recombinant proteins will be more easily produced and the use of
20 various cytokines or hormones as pharmaceutical drugs will be increasingly accelerated.

There are recognition mechanisms mediated by various oligosaccharides (sugar chains) *in vivo*. Since sugar moieties (carbohydrate moieties) attached on proteins have several effects on the transport or the metabolism of glycoproteins,
25 they have great influence on the biological activities of these proteins especially *in vivo*. Furthermore, it has been suggested that structural changes of sugar moieties of glycoproteins involved in abnormal growth or metastasis of cancer cells. Hence, it is considered that when various proteins are used as drugs, technology for producing various glycoforms of glycoproteins with distinct

carbohydrate structures using genetic engineering techniques can serve as technology introducing new drug efficacy. For example, by using such technology, it becomes possible not only to regulate and/or determine cellular localization of glycoproteins, but also to regulate the metabolism of glycoproteins.

However, information concerning about carbohydrate structures of glycoproteins is not directly encoded in genes, so that technology controlling glycosylation cannot be achieved by genome studies or proteome studies directly.

Technology for specifying and controlling carbohydrate structures of glycoproteins has not been established yet. Now carbohydrates attached on proteins are synthesized by sequential action of various glycosyltransferases (e.g., see JP Patent Publication (Kokai) No. 11-42096 A (1999)). In this procedure, it takes 2 to 3 months for synthesizing oligosaccharides by using manual operation, and a few days are required even when a synthesizer is used. However, recombinant proteins expressed in *E. coli* have not been glycosylated and moreover, in the case of yeast, carbohydrate moieties on glycoproteins are different from those of humans. Based on this reason, it is difficult to obtain useful recombinant glycoproteins as pharmaceutical drugs.

Recently, needs for oligosaccharides as pharmaceutical drugs is increasing in the field of medicine. For example, a disease such as the congenital disorder of glycosylation type Ib that is an infant metabolic disease is treated by administering oligosaccharides deficient in such patients (Alper, J., Science, 291: 2339, 2001). However, synthesis of oligosaccharides is difficult technically because of the reasons mentioned above and also oligosaccharides are not available because these are very expensive.

Therefore, techniques for producing various kinds of oligosaccharide and for convenient and rapid screening method for useful glycoproteins have been desired.

SUMMARY OF THE INVENTION

Objects of the present invention are to provide an easy and rapid method for changing carbohydrate moieties of glycoproteins and also a method for producing oligosaccharides from thus obtained glycoproteins. Further object of the present invention is to provide a method for preparing a cell expressing a glycoprotein with different glycoform and for producing an carbohydrate library (sugar chain library).

As a result of intensive studies to achieve the above objects, the present inventors have focused on the fact that structures of carbohydrate moieties of glycoproteins are recognized during sorting process of newly synthesized glycoproteins within the cells. And, they found that carbohydrate structures attached on glycoproteins can be changed and controlled by altering the carbohydrate-binding specificities of cargo receptors that are involved especially in this sorting process. Thus, the present inventors have completed the present invention.

Disclosed herein is a method for modifying a carbohydrate moiety of a glycoprotein, which comprises altering a carbohydrate recognition domain of a cargo receptor to modify a carbohydrate moiety of a glycoprotein. Specifically, the method for modifying a carbohydrate moiety of a glycoprotein comprises the following steps of:

- (a) changing a nucleotide sequence encoding a carbohydrate recognition domain of a cargo receptor gene;
- (b) introducing the above cargo receptor gene into a cell; and
- (c) expressing a glycoprotein having a modified carbohydrate moiety in the above cell.

In the above method for modifying a carbohydrate moiety of a glycoprotein, the cargo receptor is preferably VIP36 and/or ERGIC-53.

Furthermore, examples of the glycoprotein include membrane-bound proteins and secretory proteins.

Also disclosed is a glycoprotein, wherein a carbohydrate moiety is modified by the above method for modifying a

carbohydrate moiety.

Also disclosed is a method for producing a modified oligosaccharide, which comprises cleaving an oligosaccharide from the above glycoprotein.

5

Also disclosed is a modified oligosaccharide, which is produced by the above production method.

Further disclosed is a method for preparing a cell expressing a glycoprotein with a modified carbohydrate moiety, which comprises altering a carbohydrate recognition domain of a cargo receptor to modify a carbohydrate moiety of a glycoprotein. Specifically, the preparation method comprises the following steps of:

- (a) changing a nucleotide sequence encoding a carbohydrate recognition domain of a cargo receptor gene;
- 15 (b) introducing the above cargo receptor gene into a cell;
- (c) expressing the above cargo receptor gene in the above cell; and
- (d) selecting the cell expressing a glycoprotein having a modified carbohydrate moiety.

Furthermore, the above preparation method may comprise the following steps (e) or (f) (where, in this case, the order of the steps is not specifically limited) of:

- (e) introducing the gene of a desired protein into a cell; and
- (f) obtaining a cell expressing a desired glycoprotein having a modified carbohydrate moiety.

25 In the above preparation method, the cargo receptor is preferably VIP36 and/or ERGIC-53.

In addition, examples of the glycoprotein include a membrane-bound protein and a secretory protein.

Also disclosed is a cell expressing a glycoprotein with a modified carbohydrate moiety, which is prepared by the above preparation method.

30

Furthermore, the present invention relates to a method for producing a glycoprotein with a modified carbohydrate moiety, which comprises culturing the

above cell and collecting a glycoprotein with a modified carbohydrate moiety from the obtained culture.

Furthermore,

disclosed is a method for constructing a

5 modified carbohydrate library, which comprises introducing random mutations into a carbohydrate recognition domain of a cargo receptor gene and expressing a glycoprotein having a modified carbohydrate moiety. Specifically, the preparation method comprises the following steps of:

10 (a) introducing random mutations into a nucleotide sequence encoding a carbohydrate recognition domain of a cargo receptor gene;

(b) introducing the cargo receptor gene having the above random mutations into each of a plurality of cells; and

(c) expressing the above cargo receptor gene having random mutations introduced therein in each of the above plurality of cells.

15

Also disclosed is a method for screening for a

test substance interacting with a specific carbohydrate moiety of a glycoprotein or an oligosaccharide cleaved from a glycoprotein or a specific oligosaccharide using the above cell expressing a glycoprotein having a modified carbohydrate moiety. Specifically, the screening method comprises the following steps of:

20

(a) bringing a cell expressing a glycoprotein having a modified carbohydrate moiety into contact with a test substance; and

(b) determining the interaction between the glycoprotein or the carbohydrate moiety with the test substance.

25 The above screening method may also comprise a step of growing the cells expressing the glycoprotein with a modified carbohydrate moiety. Furthermore, the above screening method may comprise a step of screening for a cell expressing a desired glycoprotein with a modified carbohydrate moiety or a desired carbohydrate moiety (oligosaccharide) on the cell surface.

In one aspect of the present invention, there is provided a method for modifying a carbohydrate moiety of a glycoprotein in a cell in culture, which comprises altering at least one amino acid in a carbohydrate recognition domain of a cargo receptor in a cell, expressing the cargo receptor in the cell, and expressing a glycoprotein with a modified carbohydrate moiety in the cell, wherein the cargo receptor is VIP36 and/or ERGIC-53.

In another aspect of the present invention, there is provided a method for producing an oligosaccharide, which comprises altering at least one amino acid in a carbohydrate recognition domain of a cargo receptor in a cell in culture, expressing the cargo receptor in the cell, expressing a glycoprotein with a modified carbohydrate moiety in the cell, and cleaving an oligosaccharide from the glycoprotein, wherein the cargo receptor is VIP36 and/or ERGIC-53.

In another aspect of the present invention, there is provided a method for preparing a cell expressing a glycoprotein with a modified carbohydrate moiety, which comprises altering at least one amino acid in a carbohydrate recognition domain of a cargo receptor in a cell in culture, expressing the cargo receptor in the cell, and selecting the cell expressing a glycoprotein with a modified carbohydrate moiety, wherein the cargo receptor is VIP36 and/or ERGIC-53.

In another aspect of the present invention, there is provided a cell expressing a glycoprotein with a modified carbohydrate moiety, which is prepared by the method of the invention, and wherein said cell is in culture.

In another aspect of the present invention, there is provided a method for constructing a cell library comprising a plurality of cells in culture, each expressing a glycoprotein with a modified carbohydrate moiety, which comprises introducing random mutations into a nucleotide sequence of carbohydrate recognition domain of a cargo receptor gene, introducing the cargo receptor gene having the above random mutations into each of a plurality of cells, expressing the cargo receptor gene in each of the plurality of cells, and expressing a glycoprotein with a modified carbohydrate moiety in each of the plurality of cells, wherein the cargo receptor is VIP36 and/or ERGIC-53.

In another aspect of the present invention, there is provided a method for screening for a test substance interacting with a glycoprotein or an oligosaccharide, which comprises contacting, in culture, the cell expressing the glycoprotein with a modified carbohydrate moiety according to the invention or the cell library that is constructed by the method according to the invention with a test substance, and determining the interaction between the glycoprotein or the carbohydrate moiety with the test substance.

The present invention is explained in detail as follows. The present application claims the priority of Japanese Patent Application No. 2002-238559, which was filed on August 19, 2002, and includes the contents as disclosed in the specification and/or drawings of the above patent application.

The present invention has been completed for the purpose of constructing carbohydrate library (sugar chain library, oligosaccharide library) containing various sugar structures and glycoforms. The present inventors have conducted studies focusing on the fact that cargo receptors recognize glycoproteins in the secretion pathway of glycoproteins in eukaryotic cells so as to be involved in the processing steps of carbohydrate moieties attached on glycoproteins. Hence, the present inventors have determined putative carbohydrate recognition domain of cargo receptors and have succeeded in modifying carbohydrate moieties of expressed glycoproteins by altering such domains.

1. Cargo receptor

"Cargo receptor" is a general nomenclature for animal lectins playing important roles in quality control and sorting of glycoproteins. As cargo receptors, ERGIC-53 involved in transport of glycoproteins from the endoplasmic reticulum (ER) to the Golgi and VIP36 involved in quality control of glycoproteins in the Golgi (Hauri, H-P, et al., FEBS Letters 476 (2000) 32-37) are currently known. As shown in Fig. 1, after being synthesized in a form having carbohydrates added in the ER within eukaryotic cells, carbohydrate moieties (sugar moieties) of glycoproteins are subjected to processing in the Golgi. In secretory pathway, newly synthesized proteins are folded correctly in the ER and then transported between organelles by transport vesicles. During this process, proteins are glycosylated, sorted selected, and directed to move toward a site where each protein should function. Cargo receptors existing in the transport vesicles recognize carbohydrate moieties of glycoproteins and select proteins to be transported outside the cells.

During translation process, oligosaccharide is transferred to the Asn-Xaa-Ser/Thr peptide sequence (Xaa represents any amino acid other than proline) of proteins (Kornfeld R and Kornfelds, Ann Rev Biochem, 1985, 54:

631-664). The oligosaccharides added herein are oligosaccharides transferred from a lipid intermediate and contains 14 sugar units composed of mannose, glucose, and N-acetylglucosamine (GlcNAc). In the ER, the carbohydrate moiety of glycoproteins (e.g., a glucose residue located outermost part of the glycoprotein) is recognized by a lectin. Only the proteins correctly folded are subjected to removal of a glucose residue, and they are then transported to the Golgi for further modification (Teasdale RD, and Jackson MR, Annu Rev Cell Dev Biol, 1996, 12: 27-54).

Subsequently, in the ER-Golgi intermediate compartment (ERGIC, the zone between ER and the Golgi), ERGIC-53, one of the cargo receptors, functions in the transport of glycoproteins from the ER to the ERGIC. In the Golgi, further modifications of oligosaccharide are carried out by various glycosyltransferases and glycosidases, whereby finer oligosaccharide structures containing such as GlcNAc, galactose, fucose, and sialic acid are mainly formed.

However, in this oligosaccharide processing, complete carbohydrate structures (glycoforms) are not always formed, and glycoproteins without functional activity are also generated. It is thought that VIP36 plays function in quality control of sugar chains attached on proteins and functions in the transport of glycoproteins from the trans-Golgi to the cis-Golgi or ERGIC (Fullekrug J, J Cell Sci, 1999, 112 (Pt 17): 2813-21). VIP36 prevents incomplete glycoproteins from being secreted by returning the incomplete glycoproteins to the initial stage of oligosaccharide processing in ERGIC or the cis-Golgi.

As described above, the term "cargo receptor" in the present invention is not specifically limited, as long as it recognizes sugar chains (carbohydrate moieties) attached on glycoproteins and is involved in the transport of glycoproteins required *in vivo*. In addition to recently discovered-ERGIC-53 and VIP36, cargo receptors that have similar functions and will be discovered in the future are also encompassed in the scope of the present invention.

The currently discovered 2 types of cargo receptors have already been

isolated. Regarding ERGIC-53, human ERGIC-53 has been registered under GenBank accession number of X71661. Its nucleotide sequence is shown in SEQ ID NO: 1 and its amino acid sequence is shown in SEQ ID NO: 2. Furthermore, regarding VIP36, a human GP36b glycoprotein has been registered under
5 GenBank accession number of U10362 (its nucleotide sequence is shown in SEQ ID NO: 3 and its amino acid sequence is shown in SEQ ID NO: 4) and canine (*C. familiaris*) VIP36 has been registered under GenBank accession number of X76392.

10 Cargo receptor is known to have a "carbohydrate recognition domain (also referred to as CRD)" at its central portion, which recognizes a glycoform (carbohydrate moiety) and binds to glycoproteins (Hauri, H-P. et al., Journal of Cell Science, 113:587-596, 2000). The present inventors have discovered that
15 carbohydrate moieties of glycoproteins on the cell surface or secreted outside the cell can be modified by altering the carbohydrate recognition domain of a cargo receptor, so as to change the glycoform (carbohydrate moiety) to be recognized by the cargo receptor within the cells, resulting in a change in its quality control or sorting process for glycoproteins. The method for modifying a carbohydrate moiety of a glycoprotein and the method for preparing a cell expressing a
20 glycoprotein with a modified carbohydrate moiety (with different glycoform) according to the present invention will be described as follows.

2. Alteration of carbohydrate recognition domain of cargo receptor

(1) Carbohydrate recognition domain

25 Through comparison of homology with those of *Leguminosae* lectins, the present inventors have specified putative-carbohydrate binding domains, which are particularly important for determining carbohydrate (sugar chain) specificities of cargo receptors. The putative carbohydrate-binding domain corresponds to nucleotides from 454 to 480 of the nucleotide sequence of human ERGIC-53

cDNA (SEQ ID NO: 1; "a" of "atg" (translation initiation) is determined to be 1) and amino acids from 152 (Asp) to 160 (Lys) of ERGIC-53 amino acid sequence (SEQ ID NO: 2). The putative carbohydrate-binding domain of human VIP36 corresponds to nucleotides 484 to 510 of VIP36 cDNA (SEQ ID NO: 3) and amino acids 162 (Asp) to 170 (Thr) of VIP36 amino acid sequence (SEQ ID NO: 4). Carbohydrate-binding domains of non-human cargo receptors can also be assumed based on homology with human cargo receptors.

The present invention is characterized in that a carbohydrate recognition domain of a cargo receptor, particularly a carbohydrate-binding domain, is altered. In the present invention, the term "alteration of a carbohydrate recognition domain" means that when a cargo receptor is expressed as proteins, its carbohydrate recognition domain or its carbohydrate-binding domain differs from that of native one in terms of sequence and/or structure; or that a carbohydrate moiety (sugar chain) to be added differs from that of native protein to be expressed in cells. Hence, in addition to the above described specific sequences, alteration of a cargo receptor, whereby a carbohydrate moiety differing from that to be added before alteration, is also encompassed in the term "alteration of a carbohydrate recognition domain" according to the present invention.

In alteration of a carbohydrate recognition domain, any number of any amino acids can be changed and they are not particularly limited. However, when a carbohydrate recognition domain is altered by introducing mutations, among amino acid residues belonging to a carbohydrate recognition domain, aspartic acid (Asp) is important as an amino acid to be coordinated at Ca and Mn ions, and asparagine (Asn) is important because its side chain forms a cooperative hydrogen bond with sugars. Asparagine is also important as an amino acid residue to be coordinated and bound to Ca ions. This means that these amino acids may be greatly involved in keeping the structure of a carbohydrate-binding loop of cargo receptor and its binding to sugars. Among the above putative 9-amino acid-long loop determining carbohydrate-binding specificity, it is

preferred not to introduce any mutations into amino acids 152 (Asp) or 156 (Asn) in the case of ERGIC-53, or into amino acids 162 (Asp) or 166 (Asn) in the case of VIP36, so as to conserve the amino acids.

5 (2) Introduction of random mutation into carbohydrate recognition domain

In the present invention, it is preferred to alter a carbohydrate recognition domain (or a carbohydrate-binding domain) of a cargo receptor by introducing mutations into its gene. A technique for introducing mutations into a partial region of a gene is known in the art. When correlation between mutations to be
10 introduced and carbohydrate-binding specificities thus obtained is unknown, a carbohydrate recognition domain of a cargo receptor is randomly mutated, and then confirmed whether glycoforms (carbohydrate moieties) structures of glycoproteins is changed or not.

To introduce mutations randomly into a partial region of a gene, a random
15 mutagenesis known in the art can be employed. Examples of such a technique are not limited and include a method using degenerate oligonucleotides, a linker scanning method, and a method based on PCR. Regarding these techniques, please see, for example, "Molecular Biology Experimental Protocol I" (particularly chapter 8) (Ausubel, FM et al., translated by Kaoru Saigo and
20 Yumiko Sano, 1997, MARUZEN CO., LTD.) and "New Genetic Engineering Handbook" (particularly pages 216 to 226) (3rd revised edition, edited by Masami Muramatsu and Masashi Yamamoto, 1999, YODOSHA CO., LTD.). In the present invention, to achieve the purpose of preparing as many types of random oligonucleotides as possible in large quantities, a technique for introducing
25 random mutations in combination with polymerase chain reaction (PCR method) using degenerate oligonucleotides as primers is preferred. Such a technique for altering a carbohydrate recognition domain of a cargo receptor by the PCR method using degenerate oligonucleotides will be described in detail as follows.

(2-1) Principle

The method using degenerate oligonucleotides is based on the phenomenon that degenerate oligonucleotides having random mutations can be synthesized by adding nucleotides other than normal nucleotides at the time of oligonucleotide synthesis. By utilization of this technique, degenerate oligonucleotides having various mutations introduced into regions corresponding to carbohydrate recognition domains of cargo receptors can be obtained. The method using degenerate oligonucleotides is advantageous in that the mutation rate can be controlled by increasing or decreasing the addition ratio of nucleotides (e.g., to obtain a mutation rate of 10% per nucleotide, 3 other nucleotides (3.33% each) are added to 90% of normal nucleotides).

Many kits are commercially available for preparing degenerate oligonucleotides. For example, the ExSiteTM PCR-Based Site-Directed Mutagenesis Kit (Stratagene) or LA PCRTM *in vitro* Mutagenesis Kit (TaKaRa) can be used. When such a kit is utilized, various mutants having mutations such as a point mutation and deletion and/or insertion of several nucleotides can be conveniently prepared by changing primer design.

(2-2) Construction of random library

First, to obtain cargo receptor genes containing carbohydrate recognition domains with various mutations, random libraries of cargo receptor genes containing carbohydrate recognition domains wherein mutations have been randomly introduced are constructed using random primers comprising the above degenerate oligonucleotides.

As a random primer, a degenerate oligonucleotide hybridizing to a region around a carbohydrate recognition domain is used. A method for designing a random primer is known in the art, and a degenerate oligonucleotide can be easily determined by persons skilled in the art, as in the case of PCR reaction conditions and the like.

Random primers that can be utilized in the present invention are shown below, but they are not limited thereto:

· Primers to amplify the latter half fragment on the 3' terminal side containing a carbohydrate recognition domain of VIP36:

5 VIPran3: 5'-CGT GCT CTA GAC NNK NNK NNK AAT NNK NNK NNK
NNK GAG CGC GTG TTC CCG TA-3', (SEQ ID NO: 7: in the sequence, N
denotes A, T, G, or C and K denotes G or T)

VIPran5: 5'-ATC GTC TTA AGC ACT CAG TAG AAG CGC TTG-3' (SEQ
ID NO: 8)

10 · Primers to amplify the latter half fragment on the 3' terminal side containing a
carbohydrate recognition domain of ERGIC-53 (in the sequence, the underlined
site denotes a restriction enzyme site):

ERGIC-BF: 5'-CGTATCTAGATXXXKXXXKXXKAATXXXKXXXKXXXKA
ATAATCCTGCTATAGTAATTAT-3' (SEQ ID NO: 14: in the sequence, K denotes
15 G or T, and X denotes any one of A, T, G, or C)

ERGIC-BR: 5'-CGTACTTAAGTGGTAGTCAAAAGAATTTTTTG-3' (SEQ
ID NO: 15)

20 A method for synthesizing primers designed as described above is known
in the art. For example, a general oligonucleotide synthesis method such as a
phosphoamidite method can be employed.

Next, through the use of the above-designed primers, amplification
reaction is carried out using a cargo receptor cDNA or a cDNA library or mRNA
as a template. Examples of amplification reaction are not limited and include
25 polymerase chain reaction (PCR) and a LAMP method (Loop-mediated Isothermal
Amplification). Extraction of mRNA and construction of a cDNA library can be
carried out according to conventional methods.

Using the thus obtained mRNA as a template, single-stranded DNA can be
synthesized using random primers and reverse transcriptase. Double stranded

DNA is then synthesized from the single-stranded DNA. In the case of the PCR method, double-stranded DNA can be obtained. Subsequently, the thus obtained double-stranded DNA is incorporated into an appropriate cloning vector so as to construct a recombinant vector. Then, the recombinant vector can be transformed into *Escherichia coli* or the like, and then transformants are selected using tetracycline resistance, ampicillin resistance, or the like as an indicator, so that random libraries can be obtained.

Next, a portion containing a target cargo receptor gene can be cloned from the obtained clones. For DNA cloning, for example, a TA cloning method can be employed. The TA cloning method can be conducted using a commercially available kit such as a TA cloning kit (Invitrogen Corporation).

For the isolated DNA clones obtained in the above screening, the DNA nucleotide sequences are determined using amplification products as templates.

Nucleotide sequences can be determined by a known techniques such as Maxam and Gilbert's chemical modification method or the dideoxynucleotide chain termination method using an M13 phage. In general, sequencing is carried out using an automated system for determining nucleotide sequences (e.g., DNA Sequencer LONG READER 4200 produced by LI-COR, INC.).

In addition to the above-described methods, based on the nucleotide sequence of a cargo receptor gene, through the use of technology for artificially deleting, substituting, or inserting one to several nucleotides into the nucleotide sequence, such as the site-directed mutagenesis method, mutants having carbohydrate recognition domains with different sequences while maintaining the functions of a cargo receptor can be prepared. For example, for site-directed mutagenesis whereby one to several nucleotides are substituted, mutants can be obtained and utilized according to the technology as described in, for example, Proc. Natl. Acad. Sci. USA 81 (1984) 5662-5666, WO85/00817 (PCT Pamphlet), Nature 316 (1985) 601-605, Gene 34 (1985) 315-323, Nucleic Acids Res. 13

(1985) 4431-4442, Proc. Natl. Acad. Sci. USA 79 (1982) 6409-6413, or Science 224 (1984) 1431-1433. Moreover, these mutants can be prepared through the use of a commercially available kit (Mutan-G and Mutan-K (Takara)). Furthermore, error-prone polymerase chain reaction (error-prone PCR) is also known as a method for preparing mutants. In this method, mutation of one to several nucleotides can be introduced by selecting conditions with a low degree of strictness (fidelity) for amplification (Cadwell, R. C. and Joyce, G. F. PCR Methods and Applications 2 (1992) 28-33; Malboeuf, C. M. et al. Biotechniques 30 (2001) 1074-8; Moore, G. L. and Maranas C. D. J. Theor. Biol. 7; 205 (2000) 483-503).

In the case of random mutations, for example, among nucleotides corresponding to a carbohydrate recognition domain of VIP36, 14 nucleotides are each of A, T, G, or C, and 7 nucleotides are each of G or T, so that at least $4^{14} \times 2^7$ (that is, 3.4×10^{10}) combinations of sequences into which mutations have been randomly introduced are possible. Furthermore, for example, among 9 amino acids corresponding to a carbohydrate recognition domain of ERGIC-53, mutations can be introduced into 7 amino acids. Hence, 14 nucleotides are each of A, T, G, or C and 7 nucleotides are each of G or T, so that there are at least $4^{14} \times 2^7$ (that is, 3.4×10^{10}) combinations of sequences into which mutations have been randomly introduced, as in the case of VIP36. Moreover, by the introduction of mutations such as those involving deletion or insertion, the resulting random libraries will contain a greater number of various sequences.

(2-3) Random vector

A vector for cell transfection is constructed using the above-obtained random libraries of cargo receptor genes containing carbohydrate recognition domains having various mutations.

A random vector to be transfected into cells can be obtained by ligating DNA of the above random library into an appropriate vector. A transfected cell

can be obtained by introducing the above random vector into a host so that a target cargo receptor gene can be expressed.

As a vector, a vector known in the art as a vector for transfection can be used. Examples of such a vector include plasmid DNA, phage DNA, animal
5 virus vectors e.g., retroviruses or vaccinia viruses, insect virus vectors e.g., baculoviruses, bacterial artificial chromosome (BAC), and yeast artificial chromosome (YAC).

To insert a cargo receptor gene of the random libraries into a vector, for example, a method that involves cleaving a purified DNA with an appropriate
10 restriction enzyme and inserting the DNA into a restriction enzyme site or a multi-cloning site of an appropriate vector DNA so as to ligate the DNA to the vector can be employed.

It is necessary to incorporate a cargo receptor gene into a vector so that the functions of the gene can be exerted. Hence, in addition to a promoter and a
15 cargo receptor gene, a cis-element such as an enhancer, a splicing signal, a polyA addition signal, a selection marker, a ribosome-binding sequence (SD sequence), or the like can be ligated to a recombinant vector, if desired. In addition, examples of a selection marker include a dihydrofolate reductase gene, an ampicillin resistance gene, and neomycin resistance gene.

20 To ligate a DNA fragment to a vector fragment, a known DNA ligase can be used. Next, a DNA fragment and a vector fragment are annealed and then ligated, so that a random vector is constructed.

(2-4) Transfection into cell

25 Hosts used for transfection are not specifically limited, as long as they are eukaryotic cells. Examples of such a host include yeast, animal cells (e.g., COS cells, CHO cells, or MDCK cells), and insect cells. When the present invention is applied to production of proteins derived from an animal such as a human, it is particularly preferable to use animal cells.

When yeast is used as a host cell, for example, *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, or the like is used. In this case, a promoter is not particularly limited, as long as it can direct a gene expression in yeast. A method for introducing a recombinant vector into yeast is not particularly limited, as long as it is a method for introducing DNA into yeast. Examples of such a method include an electroporation, a spheroplast method, and a lithium acetate method.

When an animal cell is used as a host, simian COS-7 cells, simian Vero cells, Chinese hamster ovary cells (CHO cells), mouse L cells, rat GH3, human FL cells, Mardin Darby canine kidney cells (MDCK cells), or the like are used. As a promoter, SR α promoter, SV40 promoter, LTR promoter, CMV promoter, or the like is used. In addition, for example, a promoter of human cytomegalovirus early gene may be used. Examples of a method for introducing a recombinant vector into an animal cell include an electroporation method, a calcium phosphate method, and a lipofection. A method for introducing a vector into an animal cell can be conveniently carried out using a commercially available kit, such as Effectene® transfection reagent (QIAGEN) or LipofectAMINE reagent (Invitrogen) according to the manufacturer's protocols.

When an insect cell is used as a host, Sf9 cells or the like can be used. Examples of a method for introducing a recombinant vector into an insect cell include a calcium phosphate method, a lipofection, and an electroporation.

Transfected cells can be selected utilizing the properties of a marker gene that is a constituent of a gene to be introduced. For example, when a neomycin resistance gene is used, cells exhibiting resistance against the G418 drug are selected.

Whether or not a target cargo receptor gene is incorporated into cells can be confirmed by the PCR method, the Southern hybridization method, or the like. For example, DNA or mRNA is prepared from transfected cells, primers specific to an introduced DNA are designed, and then PCR is performed. Subsequently,

amplification products are subjected to agarose gel electrophoresis, polyacrylamide gel electrophoresis, capillary electrophoresis, or the like stained using ethidium bromide, SYBR Green fluid, or the like, and then detected as a single band, so that the introduced DNA can be confirmed. Furthermore, PCR is performed using primers previously labeled with fluorescent dye or the like, so that amplification products can also be detected. Furthermore, a method that involves causing amplification products to bind to a solid phase such as a micro plate and confirming the amplification products by fluorescence reaction, enzyme reaction, or the like can be employed.

(3) Separation

After alteration of a carbohydrate recognition domain of a cargo receptor as described above, cells expressing a specific glycoprotein with a modified carbohydrate moiety (different glycoform) can be separated based on its carbohydrate moiety (glycoform).

A method for separating transfected cells based on the specific carbohydrate moiety is not particularly limited, as long as it is based on techniques for identifying a carbohydrate moiety (glycoform) known in the art. In the present invention, because of its convenience, cells are preferably separated by identifying a carbohydrate moiety of a glycoprotein expressed on the cell surface of each transfected cell utilizing a plural number of types of plant lectins having carbohydrate-binding specificities.

Examples of plant lectins include *Agaricus bisporus* (ABA) lectin, Jack bean (*Canavalia ensiformis*) (ConA) lectin, *Datura stramonium* (DSA) lectin, *Lens culinaris* (LCA) lectin, *Lotus Itetragonolous* (Lotus) lectin, *Maackia amurensis* (MAM) lectin, *Phaseolus vulgaris* lectin having homotetramer E-subunits (PHA-E₄), *Phaseolus vulgaris* lectin having homotetramer L-subunits (PHA-L₄), Caster bean (RCA120) lectin, and wheat germ (WGA) lectin.

Detailed studies have been conducted concerning plant lectins. For

example, as shown in the following Table 1, the sugar specificities have been precisely analyzed.

Table 1

Lectin	Sugar (carbohydrate) specificity	Carbohydrate type
ABA	D-Gal	O-linkage
ConA	α -D-Man, α -D-Glc	N-linkage
DSA	β -D-GlcNAc, (β 1-4GlcNAc) _n	
LCA	α -D-Glc, α -D-Man	N-linkage
Lotus	α -L-Fuc	
MAM	SA α 2-3Gal	N- or O-linkage
PHA-E ₄	D-GalNAc	N-linkage
PHA-L ₄	D-GalNAc	N-linkage
RCA120	β -D-Gal	N- or O-linkage
WGA	D-GlcNAc (bisecting)	N- or O-linkage

As a plant lectin, for example, as a biotinylated lectin, Biotin-Lectin set I and II (HONEN Corporation (J-OIL MILLS, Inc.)) are commercially available.

Regarding studies on plant lectins and oligosaccharides or carbohydrates, on the homepage of HONEN Corporation, with reference to protocols for carbohydrate analysis and lectin-related information, plant lectins other than those listed in Table 1, sugar specificities thereof, techniques for purifying glycoproteins are published (see <http://www.honen.co.jp/finechem/>; <http://www.j-oil.com/finechem/>).

The type of a modified carbohydrate moiety can be determined utilizing sugar specificities of the above plant lectins. A method for detecting cells having carbohydrate moieties bound to specific plant lectins is not particularly limited, as long as it is a technique known in the art. For example, such cells can be detected by a technique for detecting a labeled-plant lectin, or the like.

Preferably, to separate cells having carbohydrate moieties bound to labeled plant lectins, a technique (Magnetic Cell Sorting; MACS method) that involves performing secondary labeling using magnetic beads and separating cells

utilizing magnetism, or a technique that involves sorting cells by flow cytometry based on the information of labeling can be employed (Fluorescent Cell Sorting; FACS method). When flow cytometry is utilized, cells can be sorted by analyzing labels of individual cells, so that cells having specific carbohydrate moieties can be precisely separated one by one. In the case of MACS, procedures thereof are convenient and can be performed in a short time, resulting in less damage to cells and low risk of bacterial contamination, or the like. Furthermore, regarding the above techniques for separating cells, 1 type of technique may be conducted once or several times, or 2 or more types of techniques may be combined and respectively conducted once or several times.

By subculturing of the above-separated cells, cells having specific carbohydrate moieties can be concentrated (enriched).

3. Confirmation of altered domain and modified carbohydrate moiety

As described above, correlation between altered domains and modified carbohydrate moieties can be elucidated by randomly introducing mutations into carbohydrate recognition domains of cargo receptors and then examining the carbohydrate structures (glycoforms) of the obtained glycoproteins.

Therefore, when specific alteration is carried out to obtain a specific modified carbohydrate moiety, mutations are introduced site-specifically into a carbohydrate recognition domain of a cargo receptor. As such a technique, a known technique such as a Kunkel method or a Gapped duplex method, or a related method can be employed. Mutations can be conveniently introduced using, for example, a kit for mutation introduction utilizing the site-directed mutagenesis method (e.g., Mutan-K (TAKARA BIO INC.) and Muran-G (TAKARA BIO INC.)).

As described above, specific mutations are introduced into a carbohydrate recognition domain of a cargo receptor, or mutations are randomly introduced into a carbohydrate recognition domain of a cargo receptor, and then cells expressing

proteins having the desired type of carbohydrate moiety are selected. Thus, causing proteins having desired modified carbohydrate moieties to be expressed on the cells becomes possible, and thus the modified carbohydrate moieties (or modified oligosaccharide) can be conveniently obtained in large quantities.

5

4. Preparation of cell expressing glycoprotein having modified carbohydrate moiety

As described above, when correlation between an altered domain and a modified carbohydrate moiety is determined, cells expressing glycoproteins having the specific modified carbohydrate moiety can be prepared. Alternatively, such cells can also be obtained by selecting cells expressing glycoproteins having the specific modified carbohydrate moiety from among cells wherein mutations have been randomly introduced into a carbohydrate recognition domain of a cargo receptor. In the present invention, the term "modified carbohydrate moiety" or "modified carbohydrate structure" indicates that the sequence and/or the structure of such a carbohydrate moiety differs from that of an unaltered cargo receptor. Furthermore, in the present invention, the term "glycoprotein" or "protein with or having a carbohydrate moiety" indicates a substance composed of sugars (carbohydrates) and proteins that are covalently bound to each other.

20 Proteins to which a specific modified carbohydrate moiety is bound is expressed in the above-prepared cell by conventional genetic engineering techniques so that the carbohydrate moiety can be bound to the protein. Examples of such proteins include, but are not limited to, proteins to be used as pharmaceutical products such as erythropoietins (EPO), granulocytic colony-stimulating factors (G-CSF), interleukins, and antibodies. Regarding EPO, it has already been reported that modification of the carbohydrate moiety leads to the prolonged half-life of the glycoprotein in blood. Regarding an antibody, it has also been reported that modification of the carbohydrate moiety leads to enhanced activity of the protein. Hence, oligosaccharide (carbohydrate)

processing may be able to confer effects equivalent to or better than the properties (effects) of proteins or other pharmaceutically useful properties (effects) to proteins. Moreover, proteins to which a specific modified carbohydrate moiety (oligosaccharide) is bound is not limited to proteins for pharmaceutical use. For example, proteins subjected to studies on the *in vivo* effects of carbohydrate moieties on the proteins, T cell receptors, NK cell receptors, chemokine receptors, and MHC class I and II molecules involved in intercellular recognition, adhesion molecules such as NCAM (neural cell adhesion molecule), cadherin, integrin, LFA-1 (lymphocyte function-related antigen-1), ICAM-1 (intercellular adhesion molecule-1), and GlyCAM-1, activin, Notch, Delta, and Serrate involved in development, extracellular matrices such as mucin, and collagen are also encompassed in the present invention.

To express a desired protein in the above-prepared cell, for example, as described in sections (2-3) and (2-4) of "2. Alteration of carbohydrate recognition domain of cargo receptor," a gene encoding the protein is inserted into a recombinant vector, and then the vector is transformed into or transfected into cells. At this time, to express the protein as a membrane-bound protein, in addition to a gene encoding the protein, a fusion gene is constructed to encode a secretory signal sequence for transporting the protein to the cell surface and a sequence of a transmembrane domain of cells surface-localized protein or a GPI anchor sequence on the same gene. The fusion gene is then expressed in cells. Furthermore, to express the protein as a secreted protein, a fusion gene encoding the gene sequence that encodes the protein and a secretory signal sequence on the same gene is constructed, and then the fusion gene is expressed in cells.

A secretory signal sequence (also referred to as a secretory signal or a secretory signal peptide) is generally bound to the N-terminus of proteins to be secreted outside the cell. In general, the sequence is removed when proteins to be secreted outside the cell is secreted from the inside to the outside of the cell via the cell membrane. In the present invention, any secretory signal sequences

that can transfer and express a desired protein outside the cell can be used.

Cell surface-localized proteins are those that are fixed on the cell surface layers of host cells and that exist on the cell surface. The cell surface means any of the inside of the outermost membrane (e.g., cell wall and cell membrane) of a host cell, the interface between the outermost layer and the outside of the cell membrane, and regions protruding via linkers or anchors from the outermost layer of cells. Cell surface-localized proteins are not particularly limited, as long as they enable fixation of desired proteins on the cell surface layers.

When a desired protein is expressed using the cell expressing the glycoproteins with a modified carbohydrate moiety (different glycoform) according to the present invention, the modified carbohydrate moiety is added to the protein. Hence, according to the present invention, a specific carbohydrate moiety can be bound to a desired protein.

5. Glycoproteins with a modified carbohydrate moiety

In the present invention, through the use of cells prepared as described in the above sections "2. Alteration of carbohydrate recognition domain of cargo receptor" or "4. Preparation of cell expressing glycoprotein having modified carbohydrate moiety," a glycoprotein with a modified carbohydrate moiety (with different glycoform) can be produced.

In the present invention, a glycoprotein with a modified carbohydrate moiety can be obtained by culturing the above-prepared cells and collecting the protein from the culture. The term "culture" means any of cultured cells or disrupted cells. A method for culturing transfected cells in media is conducted according to a method generally employed for culturing host cells.

As a medium for culturing a transformant obtained using a microorganism such as yeast as a host, either a natural or a synthetic medium may be used, as long as it contains carbon sources, nitrogen sources, inorganic salts, and the like,

assimilable by microorganisms, and enables efficient culture of transformants. Here, carbon sources, nitrogen sources, inorganic substances, and the like to be added to media are known in the art.

Culturing is generally carried out under aerobic conditions such as shake
5 culture or aeration and agitation culture at approximately 28°C to 40°C for approximately 18 hours to 10 days. During culturing, a roughly neutral pH is maintained, such as pH 7.4. pH is adjusted using inorganic or organic acid, alkaline solution, or the like. During culturing, antibiotics such as ampicillin or tetracycline may be added to media, if necessary.

10 When a microorganism transformed with an expression vector having an inducible promoter used therein as a promoter is cultured, an inducer may be added to media, if necessary. For example, when a microorganism transformed with an expression vector having a Lac promoter used therein is cultured, isopropyl-β-D-thiogalactoside (IPTG) or the like may be added to media. When
15 a microorganism transformed with an expression vector having a trp promoter used therein is cultured, indoleacetic acid (IAA) or the like may be added to media.

As media for culturing transfected cells obtained using animal cells as host cells, for example, generally-employed RPMI1640 media, DMEM media, or
20 HAM F10 media supplemented with 5% to 20% fetal bovine serum (FBS) or various commercially available serum-free media can be used. Culturing is generally carried out in the presence of 5% CO₂ at 37°C for approximately 18 hours to 10 days. During culturing, antibiotics such as kanamycin or penicillin may be added to media, if necessary.

25 After culturing, a target glycoprotein with a modified carbohydrate moiety (with different glycoform) can be obtained using a general means for purifying proteins. When the protein is a membrane-bound protein, since such proteins is produced on the cell surface, the proteins are extracted by disrupting and/or solubilizing the cells. Furthermore, when the protein is a secreted protein, the

proteins are collected from the culture supernatant. Subsequently, the target proteins can be isolated and purified from the above culture using one of or an appropriate combination of general biochemical methods that are employed for protein isolation and purification, such as ammonium sulfate precipitation, gel chromatography, ion exchange chromatography, and affinity chromatography.

Whether or not a target protein is obtained can be confirmed by SDS-polyacrylamide gel electrophoresis or the like.

Methods for producing a glycoprotein with a modified carbohydrate moiety utilizing cells are as described in detail above. As is known by persons skilled in the art, it is also possible to produce a glycoprotein with a modified carbohydrate moiety by modifying carbohydrate moiety in cell-free system. A kit for producing proteins utilizing cell-free system (e.g., an *in vitro* translation system) is commercially available. The present invention can be achieved utilizing such a kit. Briefly, through the utilization of an *in vitro* transcription/translation system such as TnT® Coupled Reticulocyte Lysate Systems (rabbit reticulocyte) or TnT® Coupled Wheat Germ Extract Systems (wheat germ) marketed by Promega Corporation, for example, a cargo receptor having an altered carbohydrate recognition domain and a desired protein are expressed, so that the modified carbohydrate moiety is bound to the desired protein. For details of the *in vitro* translation systems of Promega Corporation, please see the homepage thereof (http://www.promega.com/guides/ive_guide/default.htm).

As described above, the present invention is not limited to the production of a glycoprotein with a modified carbohydrate moiety in a specific cell system.

6. Production of oligosaccharide

Once a glycoprotein with a modified carbohydrate moiety is obtained as described above, an oligosaccharide can be cleaved from the protein, so that the

modified oligosaccharide can be obtained. Cleavage of such an oligosaccharide can be carried out by techniques known in the art, such as a hydrazinolysis method or degradation by enzymes. Regarding the hydrazinolysis method, a Hydraclub hydrazinolysis reagent C (HONEN Corporation) is marketed, by which
5 oligosaccharides can be cleaved according to the instructions. Regarding degradation by enzymes, for example, N-glycopeptidase or O-glycanase is allowed to react with glycoproteins, so that the oligosaccharide can be cleaved.

According to the present invention, a desired carbohydrate moiety or oligosaccharide can be produced conveniently and in large quantities.
10 Carbohydrates and oligosaccharides are required in many fields including biological and chemical fields; however, the production thereof has required much time and economic cost. The present invention is very useful in every field that requires such carbohydrates or oligosaccharides.

15 7. Carbohydrate library (Sugar chain library)

As shown in (2-2) above, a random library including sequences obtained by randomly introducing mutations into a cargo receptor is very large. Hence, by the transfection of cells using the random library of the cargo receptor, a library of cells expressing glycoproteins with different glycoforms (modified
20 carbohydrate moieties) on the cell surfaces can be constructed. In addition, the library may be composed of modified oligosaccharides or glycoproteins with different glycoforms prepared according to the present invention.

Since it is thought that the structures of carbohydrate moieties or oligosaccharides are involved *in vivo* functions, the carbohydrate library is useful
25 for carbohydrate studies. For example, a carbohydrate moiety or oligosaccharide having important functions can be searched for from the carbohydrate library, which include various carbohydrate moieties or oligosaccharides.

To select (screen for) a carbohydrate moiety or oligosaccharide having a specific structure or a specific function from the carbohydrate library, for

example, a technique for selecting (screening for) a carbohydrate moiety or oligosaccharide based on its binding to a plant lectin, an antibody, and a receptor or a technique for selecting *in vivo* radio-labeled cells based on their accumulation in organs (targeting) can be employed.

5 Furthermore, the carbohydrate library enables the use of cells expressing various glycoproteins, or oligosaccharides or glycoproteins immobilized on chips. Such chips are useful for extensively detecting (screening for) a carbohydrate moiety or oligosaccharide having a specific structure or a specific function. In contrast, oligosaccharides or glycoproteins having specific carbohydrate
10 structures or cells can be previously selected from the carbohydrate library, immobilized respectively on various fluorescence beads (Luminex Corporation) or chips, and then used. Such fluorescence beads or chips are useful for extensively detecting (screening for) substances (e.g., proteins) or cells recognizing specific carbohydrate structures. In the present invention, the term
15 "screening" means a step of selecting candidates such as substances having specific carbohydrate structures or substances specifically interacting with specific carbohydrate structures, and indicates the sifting out of numerous carbohydrate structures in a carbohydrate library so as to narrow down candidate substances, or the narrowing down of candidate substances interacting with cells
20 expressing glycoproteins having specific structures in a carbohydrate library. Specifically, the screening method of the present invention comprises, for example, the following steps of:

(a) bringing a cell expressing a glycoprotein with a modified carbohydrate moiety or a modified oligosaccharide or a glycoprotein with a modified
25 carbohydrate moiety into contact with a test substance; and

(b) examining interaction of the glycoprotein or the carbohydrate moiety (oligosaccharide) with the test substance.

In step (a), the method for contacting is not particularly limited. For example, a cell expressing a glycoprotein with a modified carbohydrate moiety or

a modified oligosaccharide or a glycoprotein with a modified carbohydrate moiety can be brought into contact with a test substance by mixing them. Furthermore, in the step (b), the method for examining interaction is not particularly limited, either. Interaction can be examined utilizing various methods known by persons skilled in the art.

The above screening method may also include a step of growing cells expressing a glycoprotein with a modified carbohydrate moiety and/or a step of screening for a cell expressing a desired glycoprotein or a carbohydrate moiety on the cell surface. For example, cells expressing a glycoprotein with a modified carbohydrate moiety included in a carbohydrate library can be grown according to a general cell growth method, so as to be able to increase the amount of the modified carbohydrate moiety. Furthermore, since a glycoprotein with a carbohydrate moiety is expressed on cells in the present invention, a specific carbohydrate moiety or oligosaccharide can also be studied utilizing techniques such as flow cytometry.

Proteins recognizing specific carbohydrate moieties are often involved in various diseases, including viral infections, bacterial infections, and the like. Thus it is desired to screen for and discover such proteins. Moreover, it is known that infection is established by the binding of specific oligosaccharides on viruses or bacteria having specific carbohydrate moieties to cells. It is also known that contact of specific carbohydrate moieties with antibodies or cells regulates the functions of such antibodies or cells. It has been desired to examine such regulatory mechanisms. Hence, it is expected that the *in vivo* regulatory mechanisms of proteins recognizing specific carbohydrate moieties or of specific carbohydrate moieties will be discovered according to the present invention, and that then target molecules (sugars) of drugs for diseases or diagnostics will become clear, thereby enabling efficient design of drugs with no side effects and higher level diagnosis of diseases.

BRIEF DESCRIPTION OF DRAWINGS

Fig. 1 shows cargo receptors (ERGIC-53 and VIP36) involved in carbohydrate processing of glycoproteins and the quality control of carbohydrates (sugars) and the outline of secretory pathway.

5 Fig. 2 shows the outline of VIP36 library construction.

Fig. 3 shows the result of introducing random mutations into VIP36. "A" shows the nucleotide sequences of the putative carbohydrate-binding domains of VIP36 and "B" shows the amino acid sequences thereof.

10 Fig. 4 shows photographs of overexpression of altered VIP36 in MDCK cells.

Fig. 5 shows the binding of plant lectins to lectin-positive (red) and lectin-negative (black) MDCK cells. The upper row shows untransfected cells, the middle row shows mutated VIP36 transfected cells, and the lower row shows untransfected control MDCK cells.

15 Fig. 6 shows the binding of PHA-E₄ and WGA to lectin-positive (red) and lectin-negative (black) MDCK cells. The uppermost row shows wild-type cells, the second row from the top shows mutated VIP36 transfected cells resulting from the 1st separation, the second row from the bottom shows mutated VIP36 transfected cells resulting from the 2nd separation, and the lowermost row shows
20 the mutated VIP36 transfected cells resulting from the 3rd separation.

Fig. 7 shows the effect of trypsinization on the binding of lectins. PBS-EDTA treatment is indicated with red, and trypsin-EDTA treatment is indicated with blue.

25 Fig. 8 is an outline showing the design of random primers for introducing random mutations into the carbohydrate-binding domain of ERGIC-53.

Fig. 9A shows a photograph showing samples prepared using an anti-FLAG antibody as an primary antibody and a goat anti-mouse IgG₁-FITC as a secondary antibody and then observed by a fluorescence microscope. As a negative control, wild-type MDCK cells were observed.

Fig. 9B shows a photograph showing samples prepared using an anti-FLAG antibody as a primary antibody and goat anti-mouse IgG₁-FITC as a secondary antibody and then observed by a fluorescence microscope. As a positive control, VIP36-FLAG clone8 (clones whose constant expression has been confirmed) was observed.

Fig. 9C shows photographs showing samples prepared using an anti-FLAG antibody as a primary antibody and goat anti-mouse IgG₁-FITC as a secondary antibody and then observed by a fluorescence microscope. ERGIC random libraries were transfected into MDCK cells, and then selection was carried out for 10 days with 1.5 mg/ml G418, and then the cells were observed.

Fig. 10 shows histograms showing the result of analyzing the cells following MACS screening using various biotinylated lectins as primary antibodies and FITC-labeled streptavidin as a secondary antibody. A black line indicates control MDCK cells, a red line indicates a (-) fraction following MACS, and a green line indicates a (+) fraction.

Fig. 11 shows a histogram showing the result of analyzing by FACS MDCK cells fractionated by MACS using PNA lectins. The binding strength of PNA (-), that of PNA (+), and that of PNA2 (+) to PNA were compared.

Fig. 12 shows photographs showing the results of western blotting carried out for PNA (-), PNA (+), and PNA2 (+) using 5 types of biotinylated lectins as primary antibodies and streptavidin alkaline phosphatase as a secondary antibody.

Fig. 13 shows the result of analyzing the carbohydrate-binding specificity of each cell fraction when FACS was carried out for a control, PNA (-), PNA (+), and PNA2 (+) using MAM or PNA as a primary antibody and streptavidin FITC as a secondary antibody.

Fig. 14 shows the outline of a technique for separating cells having specific carbohydrate moieties by flow cytometry or a magnetic cell sorting (MACS) using labeled lectins.

Fig. 15 shows the intensity of fluorescence for labeled PNA lectins in a

process where cells having carbohydrate moieties specifically binding to PNA lectins were separated by flow cytometry (FACS) and then enriched.

Fig. 16 shows the expression of carbohydrate moieties to be recognized by altered VIP36 and PNA lectins in clone 12 and control CHO cells.

5

BEST MODE OF CARRYING OUT THE INVENTION

The present invention will be hereafter described in detail by referring to examples, but the present invention is not limited by these examples.

[Example 1] Construction of VIP36 random library

10 (1) Plasmid pRc/CMV2-flag-VIPh-AflIII

In this example, in order to introduce random mutations into a portion of cDNA encoding a carbohydrate-binding domain of VIP36, the following primers were designed with randomised oligonucleotides, overlapping cDNA encoding the carbohydrate-binding domain so that when polymerase chain reaction (PCR) was
15 performed, the amplified cDNA fragments (named VIPt, nucleotide from 481 to 1071 of total size of 1407 nucleotides) contain randomly mutated carbohydrate-binding domain.

The following four primers were used for constructing VIP36 random library (Fig. 2A): VIPran1: 5'-GCA TGT CGA CAT AAC TGA CGG CAA CAG
20 TG-3' (SEQ ID NO: 5; with restriction site *HincII*: GTC GAC included at 5' end of nucleotides), VIPran2: 5'-GAG CTC TAG AAA GAT GGC TAA GCC GTG GAA-3' (SEQ ID NO: 6; with *XbaI* site: TCT AGA at 5' end), VIPran3: 5'-CGT GCT CTA GAC NNK NNK NNK AAT NNK NNK NNK NNK GAG CGC GTG TTC CCG TA-3', SEQ ID NO: 7; where N is mixture of A/T/G/C, and K mixture
25 of G/T, with *XbaI* site at 5' end), and VIPran5: 5'-ATC GTC TTA AGC ACT CAG TAG AAG CGC TTG-3' (SEQ ID NO: 8; with *BfrI* site: CTT AAG at 5' end).

VIPran1 and VIPran2 primers were used in PCR to construct 5' half of VIP36 gene (VIPh fragment, 133-480 nucleotides of the entire length of 1407 nucleotides). Primers were first phosphorylated in the mixture of: 10 µl of

VIPran1 (2 µg/µl), 10 µl of VIPran2 (2 µg/µl), 2 µl of 10 × Kination buffer A (New England Biolab), 1.5 µl of 10 mM ATP, 6 µl of water, 1.5 µl of T4 Kinase. The solution was kept at 37 °C for 2 hours. PCR was performed with reaction solution consisting of: 1.5 µl of each phosphorylated primer, 5 µl of 10 × KOD plus buffer (TOYOBO), 2 µl of MgSO₄ (TOYOBO), 2 µl of 2 mM dNTP mix, 2 µl of pBluescript-VIP36 (as template, 10 ng/µl), 3.5 µl of water and 1 µl of KOD plus (TOYOBO). PCR programme was run in either PCRexpress (Hybaid) or GeneAmp PCR system 2400 (Perkin Elmer), beginning with 94 °C for 2 min, followed by 30 cycles of 20 s at 94 °C, 30 s at 52 °C and 1 min at 68 °C, then kept at 68 °C for 5 min. Amplified VIPh fragment was harvested by 1 % agarose gel electrophoresis, subjected to gel extraction (QIAquick Gel Extraction Kit, QIAGEN), and stored in TE buffer (Fig. 2B).

VIPh fragment was ligated with pBluescript (pBluescript SK(+)) (Stratagene) at 15 °C overnight after *Sma*I digestion followed by alkaline phosphatase treatment. Thus, prepared mixture was transformed into CaCl₂ treated *E. coli* strain JM109 by heatshock method, and cultured on a LB-Amp plate with 50 µl of 5-bromo-4-chloro-3-indolyl-beta-galactoside (X-Gal) and 4 µl of isopropyl-1-thio-beta-D-galactoside (IPTG) for colour selection. Plate was incubated for over night. White-coloured colonies were selected and cultured overnight in LB medium in the presence of 100 µg/ml of ampicillin (LB-Amp medium). Plasmid DNAs were extracted from overnight-cultured medium using Plasmid Mini Kit (QIAGEN) and stored in TE buffer. pBS-VIPh vector was then digested with *Hinc*II and *Not*I in pBluescript containing VIPh fragment. Digested VIPh fragments (VIPh', with a few pBluescript nucleotides at 3' end, cut with *Hinc*II and *Not*I at each ends) were extracted using QIAquick Gel Extraction Kit and stored in TE buffer. VIPh' fragments were ligated at 15 °C overnight with pRc/CMV2-frag which had been digested with *Hpa*I and *Not*I (*Hpa*I site and *Not*I site present in flag tag and pRc/CMV2, respectively). pRc/CMV2-flag (5641 bp) was a altered pRc/CMV2 (Catlog No. V750-20, Invitrogen) which flag

sequence 5'-GAC TAC AAA GAC GAT GAC GAC AAG-3' (SEQ ID NO: 9) was inserted into between *HincII* (base pairs 1981 of sequence size 5641bp) and *HpaI* restriction sites of pRc/CMV2. Ligated mixture was transformed into *E. coli* and cultured on a LB-Amp agar plate at 37 °C overnight. Four colonies were picked up and cultured in LB-Amp medium respectively at 37 °C for overnight. pRc/CMV2-flag-VIPh was harvested by Plasmid Mini Kit, and then sequenced.

For sequencing pRc/CMV2-flag-VIPh, dideoxy method with 8.5 µl of total solution consisting of: 0.75 µl of pRc/CMV2F (forward dye primer), 0.75 µl of pRc/CMV2R (reverse dye primer), 0.5 µl of 2.5 mM dNTP, 1 µl of Thermosequenase™ (usb), 1 µl of Thermosequenase™ Reaction Buffer (usb), 1.5 µl of pRc/CMV2-flag-VIPh and 1.5 µl of water were applied. Then 16 µl of the mixture was applied into four 0.2 ml tubes each and the same amount (16 µl) of ddATP, ddTTP, ddGTP and ddCTP were added respectively. PCR was performed with the solution mixture with standard procedure: firstly, 5 min at 95 °C, followed by 30 cycles of 30 s at 94 °C, 30 s at 50 °C and 50 s at 70 °C, lastly, 50 s at 70 °C.

In order for VIPt random fragment to be inserted, AflIII linker was constructed. Oligo DNA fragment with *AflIII* restriction site (*AflIII* linker) was introduced into plasmid vector. It makes easy to insert VIPh and VIPt fragments into pRc/CMV2-flag sequentially. Two complementary oligonucleotide sequences of the linker were: 5'-CTA GAA GTC CTT AAG AGT CGG GCC-3' (SEQ ID NO: 10; *AflIII* linker 1) and 5'-CGA CTC TTA AGG ACT T-3' (SEQ ID NO: 11; *AflIII* linker 2). In the *AflIII* linker, cohesive end suitable for *XbaI* and *ApaI* (GGGCCC) sites were formed in each 5' and 3' ends, respectively.

First, mixture of: 20 µl of *AflIII* linker 1, 20 µl of *AflIII* linker 2 and 0.5 µl of 1M Tris/HCl pH7.5 were boiled at 100 °C, then cooled down to the room temperature in order to anneal to each other. Second, pRcCMV2-flag-VIPh vector was digested at its *XbaI* and *ApaI* restriction site by appropriate enzymes, then the vector was rescued by 1% agarose gel electrophoresis followed by

QIAquick Gel Extraction. Third, annealed fragments of the linker and pRcCMV2-flag-VIPh (digested at *Xba*I site in 3' end of VIPh, and *Apa*I site in pRc/CMV2) was ligated as follows: 3 μ l of 32 nM pRc/CMV2-flag-VIPh, 3 μ l of roughly 172 μ M AflIII linker, 6 μ l of Solution I (Takara) of Takara ligation kit.

5 Ligation mixture was incubated at 15 °C for 6 h or overnight.

Ligation mixture was then transformed into *E. coli* cells (JM109). In detail, 4 μ l of the reaction mixture were added into 50 μ l of CaCl₂ treated *E. coli*, chilled in 15 ml tube beforehand. It was kept on ice for 30 min, followed by incubation at 42 °C for 1 min without shaking the tube. Immediately it was
10 cooled on ice for 2 min. After transformed cells were cultured with SOC medium (SOB medium supplemented with 10 ml of 2 M glucose; SOB medium: bacto trypton 10 g, bacto yeast extract 2.5 g, NaCl 0.29 g, KCl 0.09 g, 1 M MgCl₂ + 1 M MgSO₄ mix 10 ml, per 500 ml) at 37 °C for 1 h, cells were applied on a LB-Amp plate and incubated overnight at 37 °C for colonies to grow.

15 Four colonies were picked up and cultured in LB-Amp medium overnight, followed by plasmid extraction. Of these four colonies, at least one colony was confirmed to have plasmid by digestion with AflIII followed by electrophoresis (Fig. 2C). Plasmid (pRc/CMV2-flag-VIPh-AflIII) was sequenced and stored in 100 μ l of TE buffer (350 ng/ μ l).

20

(2) VIPt insertion into pRc/CMV2-flag-VIPh-AflIII

VIPran3 and VIPran5 primers were used in PCR to construct 3' half of VIP36 gene (VIPt, 481-1071 nucleotides of the entire length of 1407 nucleotides, with mutations introduced) (Fig. 2A). A KOD dash DNA polymerase
25 (TOYOBO), with a relatively loose proofreading activity, was chosen for PCR, since VIPt fragments were to include randomly mutated nucleotides. Various PCR conditions were tested to optimise reaction conditions, as numerous amount and wide diversity of mutated VIPt fragments were required for random library construction. As a result, the optimal concentration for the randomized primer

(VIPran3 primer) was determined to 30 pmol/μl. In contrast, the concentration for the VIPran5 primer was determined to 10 pmol/μl. In particular, PCR containing 25mM MgSO₄ was selected.

KOD plus (TOYOBO) DNA polymerase was also used for PCR
5 amplification and some conditions were tested for optimisation.

VIPt fragments (Fig. 2B) were digested with *Afl*III (3' end of the fragments) and *Xba*I (5' end). Electrophoresed to remove the small digested fragments, VIPt fragments were then ligated to pRc/CMV2-flag-VIPh-AflIII, which *Xba*I site at the 3' end of VIPh and *Afl*III site in AflIII linker of
10 pRc/CMV2-VIPh-AflIII were digested (Fig. 2D). Ligation solution was incubated at 15 °C overnight. Importantly, restriction site *Afl*III was digested by restriction enzyme *Bfr*I for two reasons. First, it recognised the same sequence as *Afl*III enzyme did and, second, it was reported by the manufacturer that the site digested by *Afl*III enzyme resulted in low efficiency of ligation reaction, which
15 was critical for library construction.

Transformation into *E. coli* JM109 was done using a standard method as above.

Electroporation was also performed using ElectroMax™ DH5alpha-E™ cells (Gibco BRL, Life Technologies: Catalog No. 11319-019). Before
20 electroporation was performed, ligation solution was purified and concentrated by ethanol precipitation with standard protocol. Also, 1 ml of SOC medium in a 15 ml tube was pre-incubated at 37 °C, a cuvette was chilled on ice, and 1 μl of pRc/CMV2-flag-VIPh-VIPt DNA in another fresh 15 ml was chilled on ice. Twenty μl of DH5alpha-E™ cells was applied in the above tube containing
25 pRc/CMV2-flag-VIPh-VIPt DNA. After two times of gentle pipetting, plasmid-*E. coli* mixture was transferred to a previously chilled cuvette. Then electroporated with conditions of: 2.45kV and 129 Ω by Electro Cell Manipulator® 600 (BTX). The above condition was chosen after a brief examination of several conditions in voltage. Voltages examined were 1.5, 2.0,

and 2.45 kV. Immediately (within 1 min), 1 ml of pre-warmed SOC medium was added and mixed gently. Solution was then removed into a fresh 15 ml tube and incubated at 37 °C for 1 h. Then, each 100 µl of one-hour-cultured solution was spread onto a LB-Amp agar plate. Plates were then incubated overnight at 37 °C. Electroporation was repeated until the number of colonies formed reached 1×10^6 . Some colonies were chosen for sequence analysis to confirm whether the random mutation of pRc/CMV2-flag-VIPh-VIPt was introduced (Fig. 3). Numbers of inserted fragment in a vector, transformed by both calcium chloride method and electroporation were determined by restriction digestion with *Xba*I and *Bfr*I.

(3) Recovery of VIP36 random library

First of all, 50 ml of LB-Amp medium was added into a LB-Amp agar plate on which colonies were grown. Colonies were physically removed from the agar by gently mixing colonies with the added medium using a conradi stick (TGK). Suspension was then transferred to a fresh 50 ml tube. Suspension was then messed up to 50 ml with LB-Amp medium in order to give additional medium for cell growth. Suspension in medium were cultured overnight at 37 °C. Air conditioning was noted while incubation. Five hundred µl of overnight cultured *E. coli* suspension was recovered as a stock, stored with 17 % glycerol at - 80 °C. The above procedure was done with each single agar plate. In order to extract plasmids from the suspension, appropriate volumes of the suspension from usually ten different agar plates were mixed together. Volumes of the suspension to be mixed from each plate were determined according to the ratio of the number of colonies from each plate. This was to avoid for a particular mutated VIP36 DNA to predominate over the other ones. Plasmids were recovered from the mixture by QIAGEN Plasmid Midi Kit and stored in 100 µl of TE buffer. Then plasmids (mixture of pRc/CMV2-flag-VIPh-VIPt with putatively randomised carbohydrate recognition domains in VIPt) were pooled in thirty-two 1.5 ml tubes and used in the following experiments.

To examine the mutated VIP36 cDNA to be introduced into plasmids, a few colonies were picked up and extracted plasmid from *E. coli* cells were digested with *Xba*I and *Bfr*I. In a plate with low number of total colonies grown (usually from 40 to 200 colonies), 10 out of 12 colonies examined (83 %) contained the target plasmid, whereas 4 out of 6 colonies (67 %) had the target plasmid in a plate with high number of total colonies (from 1000 to 6000 colonies). Hence, the estimated size of the library was either 8×10^5 or 6×10^5 . Randomly mutated gene encoding carbohydrate recognition domain of VIP36 was confirmed by nucleotide sequence analysis (Fig. 3).

[Example 2] Transfection into cells

(1) Stable Transfection by Effectene™

Because VIP36 library constructed in Example 1 was stored in thirty two 1.5 ml tubes, plasmids in 117.4 µl of TE buffer was first prepared by combining portions of library solutions separately stored in thirty two independent pools. Ratio of solutions mixed was determined according to the size of independent clones including in library of each pool. This calculation was to keep equal of the diversity of randomised carbohydrate recognition domain (CRD). In detail, 2.5 µl ($0.5 \mu\text{l} \times 5$ tubes) was taken from library of the size being 500 clones, 5.4 µl ($0.6 \mu\text{l} \times 9$) from library of the size 6000 clones, 0.1 µl ($0.1 \mu\text{l} \times 1$) from library of the size 1000 clones, 1.0 µl ($1 \mu\text{l} \times 1$) from library of the size 1×10^4 clones, 66.0 µl ($6 \mu\text{l} \times 11$) from library of the size 6×10^4 clones, 1.5 µl ($1.5 \mu\text{l} \times 1$) from library of the size 1.5×10^4 clones, and 32.0 µl ($8 \mu\text{l} \times 4$) from library of the size 8×10^4 clones.

The plasmid prepared as above (named VIP36mix) was linearized by digestion with *Bgl*II and incubated at 37 °C overnight. Linearized VIP36mix was then applied to 1 % agarose gel electrophoresis and extracted from the gel. Concentration of the DNA after digestion was 475 ng/µl.

One day before transfection, Mardin-Darby canine kidney (MDCK) cells

(ATCC accession number: CCL-34) were subcultured so that the cells were 80-90 % confluent on the day of transfection.

According to procedures provided by the manufacturer, VIP36mix plasmid was transfected into MDCK cells. Four μg (i.e. 8.42 μl) of VIP36mix was applied into a 15ml tube. Then 300 μl of EC buffer (QIAGEN, provided in a kit of Effectene transfection reagent) was added and mixed gently using voltex mixer for just one second. The mixture was left at room temperature for 4 min. Fourty eight μl of Effectene reagent (QIAGEN) was added to the above mixture and voltexed gently for 10 sec. The mixture was again left at room temperature for 9 min. While the preparation of DNA, D10 medium (Dulbecco's modified Eagle's medium (DMEM; Sigma) supplemented with 10% bovine fetal serum (FCS), 10mM HEPES and penicillin (100 U/ml)-streptomycin (100 $\mu\text{g}/\text{ml}$)) was decanted and cultured MDCK cells in a plastic dish (ϕ 100 mm) was washed with 5 ml of PBS (phosphate-buffered saline). The cells were suspended in 7 ml of fresh D10 medium. In the other tube, 3ml of D10 medium was added to the DNA-reagent mixture prepared as above, mixed by gently pipetting 2 times. Immediately the mixture was applied drop by drop onto MDCK cells just prepared above. After the cells were cultured for 2 days at 37 °C in a 5 % CO₂ incubator, D10 medium was replaced and G418 was added (final concentration: 2.0 mg/ml) for selection of successfully transfected cells. Cells were left for 14 days since transfection until neomycin-resistant cells grew. pRc/CMV2 vector has a neomycin-resistant gene which was expressed when transfected successfully. 14 days after transfection, approximately 100 colonies were formed in the presence of 2.0 mg/ml of G418.

25

(2) Stable Transfection by LipofectAMINE™2000

Same amount of VIP36mix was prepared as mentioned above. Cells were prepared two days before transfection so that they were over 95 % confluent when transfection was performed. Cells were cultured in 10 ml of D10 medium.

On the day of transfection, 24 µg of VIP36mix DNA (i.e. 55 µl of 439 µg/µl DNA) was diluted into 1.5 ml of OptiMEM® I Reduced Serum Medium (Gibco BRL). At the same time, 75 µl of LipofectAMINE™2000 Reagent (Invitrogen) was added into another 1.5 ml of OptiMEM® I Reduced Serum
5 Medium and incubated at room temperature for 5 min. Then both VIP36mix DNA and LipofectAMINE™2000 Reagent in separate medium were combined and incubated at room temperature for 30 min. While VIP36mix DNA and LipofectAMINE™2000 Reagent were forming complexes, MDCK cells were washed with 5 ml of PBS two times and 13 ml of OptiMEM® I Reduced Serum
10 Medium was added. When ready, 3 ml of the mixture of VIP36 DNA and LipofectAMINE™2000 Reagent was added directly into MDCK cells drop by drop. Plate was rocked back and forth. Cells were incubated for 24 h at 37 °C in a 5 % CO₂ incubator.

After 24 h of incubation, OptiMEM® I Reduced Serum Medium was
15 removed and subcultured, with standard passage culture protocol, in 22.5 ml of D10 medium in two 15cm dishes. After 24 h later G418 was added into the two 15 cm dishes (final 2.0 mg/ml). Cells were incubated at 37 °C in a 5 % CO₂ incubator for 10 days in order for G418-resistant cells to grow. 10 days after transfection, cells were about 80% confluent in the presence of 2.0 mg/ml of
20 G418.

(3) Observation of mutated VIP36 by fluorescence microscopy

To estimate the transfection rates of MDCK cells, samples were prepared for fluorescence microscopy. Micro cover glasses (18 × 18 mm, MATSUNAMI)
25 were sterilised in 100 % ethanol and by a gas burner, and laid on the bottom of each well of a 6 well plate before cells were applied. After 4×10^4 cells per sample were passaged into a 6 well plate for 24 h, cells were washed with PBS once. Then 1 ml of 4.0 % formaldehyde in PBS was added and incubated at room temperature for 1 h to fix the cells. Fixed cells were washed by PBS once, they

were treated with 1 ml of 0.3 % TritonX-100 (Sigma) in PBS so that antibodies could permeabilize plasma membrane to bind intracellular antigens. Cells were then allowed to stand at room temperature for 20 min, followed by five-minutes-washing with PBS 3 times. Blocking was next performed by adding 1 ml of 5 % BSA (bovine serum albumin) in PBS and placed at room temperature for 15 min. Cells were washed for 5 min with PBS three times. After PBS around a cover glass was removed by swabbing, 200 μ l of anti-flag antibody (2 μ g/ml) in 5 % BSA/PBS, which was prepared from 3 mg/ml anti-flag M2 antibody (IBI), was mounted on a cover glass where cells were grown for observation. Cells were left at room temperature for 1 h for anti-flag antibody to bind flag tag of mutated VIP36. Washed for 10 min three times, blocking was done as described above. Following washing for 5 min by PBS three times, 200 μ l of fluorescein isothiocyanate (FITC)-labelled anti-mouse IgG₁ (GAM-FITC, Molecular Probe, 10 μ g/ml) in 5 % BSA/PBS was applied on a cover glass and incubated for 1 h at room temperature for GAM-FITC to bind anti-flag antibody. Then cells were washed for 10 min with PBS three times. Lastly, 3 μ l of 100 mM DAPI (4',6-diamidino-2-phenylindole dihydrochloride, Molecular Probes) and 3 μ l of COMPONENT A (antifade reagent in glycerol buffer) of Slowfade® *Light* Antifade Kit (Molecular Probes) was added on a micro slide glass (MATSUNAMI), and a prepared cover glass was placed on the slide glass, with cell-grown side of cover glass facing down to the slide glass. Sample was encapsulated by manicure (Kanebo) and observed by a fluorescent microscope (Olympus BX52, Fig. 4A-F).

Among cells captured in microscopy, it was revealed that 50 of 792 cells (6.3 %) had overexpressed mutated VIP36. The estimated number of transfected cells were, therefore, 1.26×10^5 cells per 2.0×10^6 cells. The number of 2.0×10^6 was obtained by counting confluent cells on ϕ 100 mm dish twice or three times. Representative photographs in phase contrast image (Fig. 4A or D), fluorescence image (Fig. 4B or E) and overlay of the both (Fig. 4C or F) were shown for both

transfectant and wild type MDCK cells, respectively.

[Example 3] Carbohydrate moiety-based Separation of Transfected Cells

(1) Plant Lectins.

5 Several plant lectins were used to separate transfected MDCK cells according to particular structure of oligosaccharides displayed on the cell surface. 10 kinds of lectins were used to distinguish a variety of oligosaccharides. Carbohydrate-binding specificity of lectins used were precisely analysed as shown in Table 1.

10 Biotinylated lectins (Honen Co.) were chosen so that lectin-bound cells could be recognised by Streptavidin MicroBeads (Miltenyi Biotec, colloidal paramagnetic MicroBeads conjugated to streptavidin). Lectins used were ABA lectin, ConA lectin, DSA lectin, LCA lectin, Lotus lectin, MAM lectin, Phaseolus vulgaris lectin with homotetrameric E-subunits (PHA-E₄), Phaseolus vulgaris lectin with homotetrameric L-subunits (PHA-L₄), RCA120 lectin, and WGA lectin. 15 These lectins were selected among others because most of them were known to recognise N-linked and O-linked oligosaccharides. N-linked oligosaccharides were thought to be recognized by native VIP36 lectin. For magnetic cell sorting, lectins of 1mg/ml were diluted in PBS (final 5 µg/ml) and sterilised by filtration 20 using 25 mm Acrodisc® Syringe Filter 0.2 µm (Pall Co.).

(2) Magnetic cell sorting of mutated VIP36 transfected MDCK cells

 Magnetic cell sorting (MACS), the system that separates magnetically labelled cells from unlabelled cells, was chosen to collect cells based on 25 carbohydrate moieties presented on the cell surface. MiniMACS, MACS separator for separation of cells and macromolecules, were purchased from Miltenyi Biotec. MiniMACS was suitable for separation of up to 10⁷ magnetically labelled cells, and a set of a MiniMACS Separation Unit, a MACS Mutli Stand, and MS Columns were included. Streptavidin MicroBeads

(colloidal paramagnetic MicroBeads conjugated to streptavidin) was used for indirect labelling of biotinylated lectin-bound cells.

Buffers used in this experiment were Labeling buffer (1 × PBS with 2 mM EDTA) and Separation buffer (1 × PBS with 2 mM EDTA and 0.5 % BSA) as described by the manufacturer. Both buffers were sterilised by filtration using 25 mm Acrodisc® Syringe Filter 0.2 µm. PBS-EDTA or Trypsin-EDTA was used to suspend the cells cultured on ϕ 100 mm dish.

A day before separation, mutated VIP36 transfected MDCK cells were propagated so that about 80 to 90 % confluent on the day of separation. Cells were washed with PBS twice and treated with either Trypsin-EDTA or PBS-EDTA for 20 min. After harvesting the cells were suspended in 2 ml of D10 medium to count the number of cells. Following centrifuge at 19 G (1000 rpm) for 5 min (same centrifugation condition applied to all the centrifuge below), cells were washed once by 10 ml of PBS. Centrifuged once again, cells were then diluted in 15 ml of lectin solution (5 µg/ml). After the incubation on ice for 30 min, lectin-bound cells were collected by centrifugation. Supernatant was aspirated carefully and completely. To wash cells for optimised secondary antibody binding, 300 µl (or 1 ml) of Labeling buffer was added. Cells were washed twice. Centrifuged once, 10 µl of Streptavidin MicroBeads was added to bind biotinylated lectins. Solution was mixed well and allowed to stand at 8 °C for 15 min. MicroBeads-bound cells were then collected by centrifuge, resuspended in 500 µl of Separation buffer and placed on ice for the following separation.

Before the separation process to begin, a MS column was prepared on MiniMACS Separation Unit clinging onto MACS Multi Stand, both sterilised by 70 % ethanol.

In order to separate cells, a MS column was first prepared by adding 500 µl of Separation buffer. Then MicroBead-bound cells in 500 µl of Separation buffer were applied on the column. Applied solution was passed through by gravity flow. The flow-through, which contain negative cells, was collected in a

15 ml tube. The column were washed thoroughly by 500 μ l of Separation buffer three times. Separation buffer passed through the column in washing process was also collected in the same 15 ml tube. The MS column was then removed from MACS Multi Stand for positive cell recovery. Positive cells in the column
 5 was collected in a fresh 15 ml tube by addition of 1 ml of Separation buffer, immediately followed by firmly flushing out positive cells using the plunger provided by the manufacturer. Positively and negatively collected cells were counted by a hemocytometer (Erma) and shown in Tables 2A and 2B. In the tables, the number describing in the columns of transfected MDCK (A) and (B)
 10 indicates the result from two independent transfection experiments.

Table 2

A: Numbers of cells separated by plant lectins [$\times 10^5$].

Types of Cells MACS fraction	Transfected MDCK (A)		Tansfected MDCK (B)		Wildtype MDCK	
	positive	negative	positive	negative	positive	negative
ConA	16	1.6	2.1	5.7	4.4	0.4
LCA	11	12	3.2	3.5	3.3	1.4
PHA-E ₄	0.8	22	3.5	0.55	3.3	1.6
RCA120	no cell	no cell	n/a	n/a	n/a	n/a
WGA	13	24	5.2	6.2	2.3	1.65
ABA	9.2	18	5.8	12	4.3	0.85
PHA-L ₄	16	9.2	1.6	2.1	1.85	2.95
MAM	17	20	0.38	22	0.85	4.55
Lotus	n/a	n/a	0.68	23	0.2	4.95
DSA	n/a	n/a	5	21	4.05	0.6

B: Ratio of positive and negative cells separated by plant lectins (%).

Types of Cells MACS fraction	Transfected MDCK (A)		Transfected MDCK (B)		Wildtype MDCK	
	positive	negative	positive	negative	positive	negative
ConA	96.4	9.1	26.9	73.1	91.7	8.3
LCA	47.8	52.2	47.8	52.2	70.2	29.8
PHA-E ₄	3.5	96.5	86.4	13.7	67.3	32.7
RCA120	n/a	n/a	n/a	n/a	n/a	n/a
WGA	35.1	64.9	45.6	54.4	58.2	41.8
ABA	33.8	66.2	32.6	67.4	83.5	16.5
PHA-L ₄	63.5	36.5	43.2	56.8	38.5	61.5
MAM	45.9	54.1	1.7	98.3	15.7	84.3
Lotus	n/a	n/a	2.9	97.1	3.9	96.1
DSA	n/a	n/a	19.2	80.8	87.1	12.9

All the procedures mentioned above applied to each lectin of ten examined: ConA, LCA, PHA-E₄, WGA, ABA, PHA-L₄, MAM, RCA120, Lotus and DSA lectins. For first 7 lectins experiment was independently carried out twice.

Separated cells were collected as lectin-positive or -negative fractions. The numbers of recovered cells in both positive and negative fraction were counted by a hemocytometer (Table 2A) and the ratio of separation was shown in Table 2B. Calculated ratios showed that separation ratio of PHA-E₄ in the first experiment was reversed for the second time (third row in Table 2B). Ratio of positive fraction by MAM was decreased in the second experiment from 45.5 % of total cells recovered to 1.7 % (eighth row of Table 2B). In comparison with separation ratios of wild type MDCK, positive fraction by Lotus resulted in 2.9 and 3.9 % of total cells recovered in separation of both transfectant and wild type MDCK cells surface (second row from the bottom of Table 2B). It might suggest few fucose residues are displayed on the cell. DSA lectin separation showed less positively recovered cells of transfectants than that of wild type cells (the bottom row of Table 2B).

At the time of first experiment was carried out (result of (A) in Tables 2A

and 2B), PHA-E₄ lectins were chosen as its positive fraction shared 3.5 % of the total recovered. Carbohydrate-binding specificity of the positive fraction was observed also by flow cytometric analysis (see Example 4).

5 (3) Multiple magnetic cell sorting of PHA-E₄ and WGA positive transfected cells

Two groups of mutated VIP36 transfected MDCK cells were proceeded to second and third round of magnetic cell sorting for larger extent of separation of each cell group than the separation method of the above (2). One group of transfected cells chosen were PHA-E₄ lectin positive group, the other was WGA positive one. These two groups of cells were further applied to sorting by MiniMACS three times with procedures described above, and the former and the latter enriched the positive cells and negative cells, respectively. Similarly, cells were subjected to further magnetic cell sorting three times. Both group of cells were counted by a hemocytometer (Table 3)

Table 3

The number of cells sorted by PHA-E₄ and WGA [$\times 10^5$].

No. of MiniMACS MACS fraction	MiniMACS, 1 st round		MiniMACS, 2 nd round		MiniMACS, 3 rd round	
	positive	negative	positive $\times 2$	negative $\times 2$	positive $\times 3$	negative $\times 3$
PHA-E ₄	0.8	2.2	4.5	4	3.8	10.6
WGA	5.2	6.2	4.8	4.2	6.7	1.1

(4) Magnetic cell sorting of wild type MDCK cells

20 Wild type of MDCK cells were examined by MiniMACS with procedures described above. Cells were counted as above and shown in Table 2. Biotynilated lectins used were: ConA, LCA, PHA-E₄, WGA, ABA, PHA-L₄, MAM, Lotus and DSA lectins.

25 [Example 4] Cell Surface Glycosylation Analysis by Flow Cytometry

(1) Flow cytometry of separated cells of both transfectant and wild type MDCK

cells

In this example, in order to investigate the carbohydrate structures on the cells accompanying with overexpression of mutated VIP36 gene, flow cytometric analysis was performed. Fluorescence intensity of the cells, stained with biotinylated lectin followed by streptavidin-FITC, was measured and recorded in histograms. Transfected cells positively separated once, twice or three times by MiniMACS, and transfectant negatively separated once, twice or three times were subjected to these analyses. Two groups of wild type MDCK cells separated positively or negatively by MiniMACS were also analysed to be compared with those of transfectants. In total, 53 independent groups of MDCK cells prepared by MiniMACS separation were used. Lectin-positive and -negative groups (2 groups) of both transfected and wild type MDCK cells (2 cell types) for each lectins (9 lectins; ABA, ConA, DSA, LCA, Lotus, MAM, PHA-E₄ and WGA) were subtotal of 36 groups. Enriched cell groups obtained by multiple magnetic sorting made subtotal of 8 groups. Control MDCK cells for 9 lectins were subtotal of 9 groups.

On the day before flow cytometric analysis, each group of MDCK cells was cultured in 4 ml of D10 medium in a 6 cm dish so that cells did not reach confluency when analysed.

On the day of analysis, cells in each dish was washed twice with PBS, followed by treatment with 500 µl of PBS-EDTA (or Trypsin-EDTA) at 37 °C for 30 min in a 5 % CO₂ incubator. When suspended, 250 µl of cells were transferred to 96 well plate and centrifuged at 51 G (1800 rpm) for 1 min (same condition applied to all centrifuge mentioned below). Then cells were washed by 200 µl of FACS buffer (HBSS (Gibco BRL) containing 0.1% BSA and 0.1% sodium azide). For primary staining, 50 µl of each lectin (10 µg/ml) was added to each appropriate well, followed by incubation on ice for 30 min. After lectin binding reaction, washing by 100 or 200 µl of FACS buffer followed by centrifuge and decantation was done three times. Decantation of FACS buffer

was carefully carried out by quickly turning the 96 well plate upside-down to avoid contamination. Secondary antibody binding was performed by addition of 50 µl of streptavidin-FITC (20 µg/ml) with incubation on ice for strictly 30 min. Following washing twice by 150 or 200 µl of FACS buffer, each cell pellet was
5 suspended in 200 µl of FACS buffer and removed to a 1.2 ml tube (Marsh Biomedical Products). After addition of 100 µl of 3 µg/ml propidium iodide (PI, Sigma), cells were analysed by FACScalibur® (Becton Dickson). Data analysis in a computer was carried out with CellQuest® (Becton Dickson) programme. The results are shown in Figs. 5 and 6.

10 In case of mutated VIP36 transfected cells, most of separated cells showed no significant differences in separation ratio for the first time experiment. This result was supported by flow cytometric analysis using the same lectins (Figure 5). In this example, separation of cells using MACS was not so good for
15 lectins that show slight difference in the percentage of negative cells and positive cells shown in Table 3 above. Thus, cells were well sorted using FACS as described in Example 12. PHA-E₄ + and PHA-E₄ - cells were, however, separated with apparently unique separation ratio even when using MACS. Mean values of relative fluorescence intensity measured was 1786.00 for TF-PHA-E₄ +, 649.30 for TF-PHA-E₄ -, whereas 1034.20 and 1127.68 for the
20 wild type, respectively. The mean value of non-separated wild type MDCK cells was 852.76. In the specification, "TF" means a fraction sorted from the transfected cells. Both TF-PHA-E₄ + and TF-PHA-E₄ - cells were further enriched by MiniMACS separation, and analysed by flow cytometry. Results showed that the mean values of TF-PHAE4++ (positive cells collected after two
25 MiniMACS separation, same abbreviation applies below) and TF-PHAE4-- were 1135 and 660, respectively (Fig. 6).

(2) Effect of treatment by PBS-EDTA or Trypsin-EDTA

In order to examine the effect of trypsin on cell surface glycosylation, two

independent groups of wild type MDCK cells were treated with PBS-EDTA or Trypsin-EDTA, respectively, when cells were suspended for primary staining. Flow cytometry procedures were proceeded as mentioned above (1). The results are shown in Fig. 7.

5 Out of 9 lectins used, 8 lectins showed no significant difference in binding affinity, whereas cells stained with Lotus lectin displayed higher binding affinity of trypsin treated cells (Fig. 7). In addition, it was noted that trypsin treated cells were hardly stained with PI, suggesting most of cells did not die during experiments (in the lower box of Fig. 7).

10 In Examples 1-4 above, the experiments that the carbohydrate structures on the cell surface was modified by introducing random mutations into carbohydrate recognition domain of VIP36, which involves transport of glycoprotein in secretory pathway.

15 By using lectins in flow cytometry, it was demonstrated that MDCK cells had a variety of oligosaccharides on the cell surfaces. Transfected MDCK cells sorted by PHA-E₄ lectin clearly showed a significant difference in lectin-binding activity. Also, repeated screening using lectins may enrich cells clone of which specificity for a certain carbohydrate moiety is enhanced.

20 [Example 5] Design of PCR primer for introducing random mutation for ERGIC-53

25 To introduce random mutation into a putative carbohydrate-binding domain of ERGIC-53 cDNA, the PCR method, by which introduction is carried out in two separate steps as in the case of VIP36 described in Example 1, was employed. Fig. 8 shows the correlation between designed primers and ERGIC-53. "(3)" was designed as a random primer for randomizing the putative carbohydrate-binding domain. PCR was performed using primers (1) and (2) and ERGIC-53 as a template. The thus generated DNA fragment (the first half portion not including the carbohydrate-binding domain of ERGIC-53, hereinafter

referred to as ERGIC-F) was incorporated into pRC-CMV2-CD8-FLAG (a vector prepared by ligating a CD8 signal sequence and a FLAG tag to pRC-CMV2). Subsequently, PCR was performed using the random primer (3) and a primer (4) and ERGIC-53 cDNA as a template. The thus generated DNA fragment (the
5 latter half portion including the carbohydrate-binding domain of ERGIC-53, hereinafter referred to as ERGIC-B-random) was introduced into the pRC-CMV2-CD8-FLAG wherein the ERGIC-F had been inserted. With such a technique, an ERGIC-53 random library was constructed. Since the region into which random mutations had been introduced by this technique is not amplified
10 by PCR, various mutations can be introduced evenly.

The names and the nucleotide sequences of the prepared primers are as shown below:

(1) ERGIC-FF (underlined portion corresponds to *Hinc* II site)

5'-GTACGTCTGACGGCGTGGGAGGAG-3' (SEQ ID NO: 12)

15 (2) ERGIC-FR (underlined portion corresponds to *Xba* I site)

5'-CGTATCTAGAAATATTCCAACACCATTCCA-3' (SEQ ID NO: 13)

(3) ERGIC-BF (underlined portion corresponds to *Xba* I site; K corresponds to G or T; X corresponds to any one of A, T, G, or C)

20 5'-CGTATCTAGATXXXKXXKXXKAATXXXKXXKXXKXXKAATAATCCTG
CTATAGTAATTAT-3' (SEQ ID NO: 14)

(4) ERGIC-BR (underlined portion corresponds to *Bfr* I site)

5'-CGTACTAAAGTGGTAGTCAAAAGAATTTTTTG-3' (SEQ ID NO: 15)

[Example 6] Construction of ERGIC-53 random library

25 (1) Preparation of plasmid pRC/ERGIC-F

The PCR method was performed using ERGIC-53 cDNA incorporated into pBluescript as a template, thereby amplifying the ERGIC-F gene, the first half portion not including the carbohydrate recognition domain of ERGIC-53. As primers, those designed in Example 5 above were used. ERGIC-FF was used as

a forward primer and ERGIC-FR was used as a reverse primer. A PCR reaction solution was prepared by mixing 2 μ l of the forward primer ERGIC-FF, 2 μ l of the reverse primer ERGIC-FR, 2 μ l of the template ERGIC-53 cDNA (1 ng/ μ l), 3.2 μ l of 25 mM MgSO₄ (TOYOBO), 4 μ l of 2 mM dNTPs (TOYOBO), 4 μ l of 10 $\times$ PCR buffer for KOD-PLUS (TOYOBO), 0.8 μ l of KOD-PLUS DNA polymerase (TOYOBO), and 22 μ l of Milli-Q water. PCR reaction was performed under conditions of 94°C for 2 minutes, (94°C for 15 seconds, 52°C for 30 seconds, and 68°C for 1 minute) $\times$ 30 cycles, and 68°C for 7 minutes. In addition, both primers that had been previously phosphorylated were used. From the PCR product, the target fragment ERGIC-F was separated by 1% agarose electrophoresis (Mupid-21 mini gel electrophoresis bath: COSMO BIO co, ltd.) and then purified by a Gene Clean Spin Kit (BIO101), so that insert fragments were prepared.

pBluescript II SK (+) was treated with a restriction enzyme *Sma* I (TOYOBO), dephosphorylated (treated with alkaline phosphatase (BAP) derived from *Escherichia coli*), followed by phenol/CHCl₃ extraction and ethanol precipitation, thereby obtaining a product to be used as a vector.

The above vector pBluescript II SK(+) that had been cut with *Sma* I and the DNA fragment ERGIC-F were mixed at a molar ratio of 1:10, followed by ligation. After ligation, the reaction solution was transformed into competent cells JM109 by the CaCl₂ method, and then the cells were inoculated on LB-Amp plates.

From among blue and white colonies that grew on the plates, only several white colonies were picked up and cultured overnight in 3 ml of an LB liquid medium (containing ampicillin at a final concentration of 100 μ g/ml). Plasmids were then extracted by an alkaline prep method and then subjected to insert check. To colonies for which the insert DNA fragment had been found to exist in the vector, plasmid extraction was carried out again using a Plasmid Mini Kit (QIAGEN). Thus, the sequence of the insert DNA fragment was confirmed by a

DNA sequencer (LI-COR).

3 out of 6 obtained DNA fragments could be confirmed to have correct nucleotide sequences. One of the fragments was determined to be a target vector to be obtained in this example, and then used in the following experiments.

5 Plasmids wherein the inserted DNA fragment having the correct sequence in the vector were selected, treated with restriction enzymes *Hinc* II (TOYOBO) and *Xba* I (TOYOBO), and then subjected to 1% agarose gel electrophoresis. Then, a target DNA fragment ERGIC-F was purified using a QIAquick Gel Extraction Kit (QIAGEN).

10 pRC-CMV2-CD8-FLAG (a vector prepared by ligating a CD8 signal sequence and a FLAG tag to pRC-CMV2) was treated with restriction enzymes *Hpa* I (TOYOBO) and *Xba* I (TOYOBO), subjected to 1% agarose gel electrophoresis, and then purified using a QIAquick Gel Extraction Kit (QIAGEN).

15 The above vector pRC-CMV2-CD8-FLAG (that had been cut with *Hpa* I and *Xba* I) and the above DNA fragment ERGIC-F were mixed at a molar ratio of 1:10, followed by ligation. After ligation, the reaction solution was transformed into competent cells JM109 by the CaCl_2 method, and then the cells were inoculated onto LB-Amp plates.

20 Several colonies were picked up from colonies that grew on the plates, and then subjected to insert check by the colony PCR method. As a result, those revealed to contain the insert were target pRC-CMV2-CD8-FLAG vectors having ERGIC-F incorporated therein. Hereinafter, the target vectors were referred to as pRC/ERGIC-F. For use in the following experiments, pRC/ERGIC-F was
25 purified using a Plasmid Mini Kit (QIAGEN). Furthermore, glycerol stocks of pRC/ERGIC-F were prepared and stored in a refrigerator at -80°C .

(2) Preparation of pRC/ERGIC-Random

In a manner similar to the method described in (1) above, the PCR method

was performed using ERGIC-53 cDNA as a template, thereby amplifying the latter half including the carbohydrate recognition domain of ERGIC-53, the gene of ERGIC-B-random. ERGIC-BF was used as a forward primer and ERGIC-BR was used as a reverse primer. PCR reaction was performed under conditions of 94°C for 2 minutes, (94°C for 15 seconds, 54°C for 30 seconds, and 68°C for 1 minute) × 30 cycles, and 68°C for 7 minutes.

The target fragment ERGIC-B-random was separated, and then purified using a QIAquick Gel Extraction Kit (QIAGEN).

Subsequently, the fragment was treated with restriction enzymes *Xba* I (TOYOBO) and *Bfr* I (TOYOBO), subjected to 1% agarose gel electrophoresis, and then purified using a QIAquick Gel Extraction Kit (QIAGEN). Thus an insert DNA fragment was obtained.

The vector pRC/ERGIC-F prepared in (1) above was treated with restriction enzymes *Xba* I (TOYOBO) and *Bfr* I (TOYOBO) and subjected to 0.8% agarose gel electrophoresis, thereby separating a target fragment. The fragment was then purified using a QIAquick Gel Extraction Kit (QIAGEN). Thereafter, the fragment was used as a vector.

The above vector pRC/ERGIC-F (that had been cut with *Xba* I and *Bfr* I) and the insert DNA fragment ERGIC-B-random were mixed at a molar ratio of 1:6, followed by ligation. After ligation, the reaction solution was transformed into competent cells JM109 by the CaCl₂ method, and then the cells were inoculated onto LB-Amp plates.

24 colonies were randomly picked up from colonies that grew on the plates, and then cultured overnight in 3 ml of an LB liquid medium (supplemented with ampicillin at a final concentration of 100 µg/µl), followed by plasmid extraction by an alkaline prep method. Subsequently, the plasmids were cleaved with 2 restriction enzymes *Apa* I (TOYOBO) and *Hind* III (TOYOBO), and then subjected to 1% agarose gel electrophoresis to confirm the presence of

ERGIC-random in the plasmids. Inserts were contained in 21 out of 24 plasmids picked up.

As a result of insert check, plasmids confirmed to contain the insert DNA fragment (ERGIC-B-random) were subjected to plasmid extraction (Plasmid Mini Kit (QIAGEN) was used) again. To confirm whether or not a portion corresponding to the insert DNA fragment (ERGIC-B-random) introduced in pRC/ERGIC-F had been reliably randomized by PCR, DNA sequence analysis was carried out. The nucleotide sequence to be analyzed at this time was the putative carbohydrate-binding domain of ERGIC-53, and was as short as 9 amino acids in length. Thus, the sequence was analyzed using an ABI sequencer. As a result of sequence analysis, the nucleotide sequences of the putative carbohydrate-binding domains were found to differ in all the plasmids.

(3) Construction of ERGIC-53 random library

In (2) above, pRC/ERGIC-Random (more specifically, the vector pRC-CMV2-CD8-FLAG, wherein ERGIC-53 having random mutations into the putative carbohydrate-binding domain) was prepared. Among 9 amino acids (DTFDNDGKK) of the putative carbohydrate-binding domain, 7 amino acids were randomized (DXXXNXXXX; X denotes any amino acid). However, in the present invention, there had been a need to produce many of those having various amino acids at the putative carbohydrate-binding domain. Hence, a pRC/ERGIC Random library was constructed. In addition, such a library is hereinafter referred to as an ERGIC random library.

(3-1) Examination of conditions for the construction of ERGIC random library

When the vector pRC/ERGIC-F prepared in (1) above and the insert DNA fragment ERGIC-B-random prepared in (2) above were ligated, the molar ratio of the vector to the insert was determined at 4 stages to be: 1:2, 1:3, 1:6, and 1:10. The ligated product was then transformed into competent cells JM109. In addition, the vector (approximately 6 Kb) with a concentration of 265 ng/μl and

the insert (approximately 1 Kb) with a concentration of 520 ng/ μ l were used.

Upon transformation, the amount of DNA (after ligation) to be transformed into competent cells was varied: 2 μ l, 3 μ l, and 5 μ l relative to 50 μ l of competent cells.

5 2 types of competent cells (JM109 and DH5 α) were used for transformation and then compared for efficiency (both types of cells were competent cells for use in the CaCl₂ method). In addition, the molar ratio of the vector to the insert upon ligation was 1:6.

As a result of the experiment, the number of colonies that had grown was
10 the largest in the case where the molar ratio of the vector to the insert was 1:10. Thus, a molar ratio of the vector to the insert of 1:10 was determined to be an optimum molar ratio. Furthermore, when the amount of DNA was examined, in the case of 5 μ l of DNA per 50 μ l of competent cells, the number of colonies was largest. Hence, in this experiment, it was determined to use 5 μ l of DNA that
15 had been subjected to ligation per 50 μ l of competent cells. Furthermore, the number of colonies that grew in the case where DH5 α had been used was 5 times greater than that in the case where JM109 had been used. Thus, it was determined to use DH5 α .

20 (3-2) Collection of ERGIC random library

The number of colonies that grew on the LB-Amp plates were counted for each plate.

24 colonies were randomly picked up for confirmation from colonies that grew on the plates, the number of which had been counted. These colonies for
25 confirmation were cultured overnight in 3 ml of an LB liquid medium (containing 100 μ g/ml ampicillin), followed by plasmid extraction and insert check (treated with restriction enzymes *Apa* I and *Hind* III, and then subjected to 1% agarose gel electrophoresis). 6 plasmids were randomly picked up from the plasmids confirmed to contain the insert, and then subjected to sequence confirmation (to

confirm whether or not random mutations had been introduced into the carbohydrate-binding domain) by a DNA sequencer. Based on the results of insert check and DNA sequencing, the ratio of effective clones to clones that had grown on the plates was calculated.

5 Colonies other than those for confirmation were immediately collected. Among the collected colonies, colonies in an effective number as calculated in the above method were used for ERGIC random libraries. Specific methods for collection will be described as follows.

10 15 ml of an LB liquid medium (containing 100 µg/ml ampicillin) was added to each LB-Amp plate, and then colonies were physically peeled off using a conrage stick, followed by shake-culture overnight at 37°C. Subsequently, a part (400 µl) of the culture solution per plate was stored as glycerol stock. The remaining culture solution was subjected to plasmid extraction using a Plasmid Mini Kit (QIAGEN). In addition, plasmid extraction was carried out for several
15 plates together. At this time, the culture solutions were mixed in an amount proportional to the number of colonies that had grown on each plate (when a culture solution collected from a plate on which 1000 colonies had grown was mixed with a culture solution collected from a plate on which 100 colonies had grown, the amount of the former culture solution was used in an amount 10 times
20 greater than that of the latter culture solution, and then subjected to plasmid extraction).

The number of colonies collected was approximately 238,000. When colonies for confirmation were randomly selected at the time of collection and then subjected to insert check and DNA sequencing for confirmation, the inserts
25 were contained in 20 colonies per 24 colonies on average. Regarding plasmids confirmed by DNA sequencing, the putative carbohydrate-binding domains have different nucleotide sequences. Hence, the number of effective colonies was determined to be approximately 200,000, representing 20/24 of the collected 238,000 colonies. Thus, the size of each ERGIC random library constructed at

this time was 2×10^5 . For these libraries, a glycerol stock was prepared for each plate, and then stored in a refrigerator at -80°C . Furthermore, approximately 5000 colonies mixed together were subjected to plasmid extraction, and then stored at -20°C . In the following examples, these plasmids were used in experiments.

[Example 7] Expression of ERGIC random library using MDCK cell

In this example, the ERGIC random libraries constructed in Example 6 were transfected into MDCK cells and then expressed. Subsequently, expression was confirmed by the Western blotting method (Example 8) and the indirect fluorescence antibody method (Example 9).

(1) Examination of transfection efficiency

Before transfection of the ERGIC random libraries into MDCK cells, conditions therefor were examined. Specifically, pIRES-EGFP (CLONTECH) was transfected into MDCK cells using an Effectene transfection reagent (QIAGEN) and an LipofectamineTM 2000 reagent (Invitrogen), so that EGFP genes were expressed temporarily. Subsequently, transfection efficiency was examined by measuring fluorescence intensity using a fluorescence-activated cell sorting system (hereinafter referred to as FACS).

(1-1) Examination of efficiency using Effectene transfection reagent

The expression efficiency of an Effectene transfection reagent (QIAGEN) was examined using $0.526 \mu\text{g}/\mu\text{l}$ pIRES-EGFP (CLONTECH).

Specifically, 4×10^5 cells were inoculated on a 6-well plate (FALCON 3046) on the day before transfection, and then cultured overnight at 37°C in 5% CO_2 . On the day of transfection, a medium (mixture of 500 ml of DMEM (SIGMA), 55.5 ml of immobilized fetal bovine serum (FBS; INTERGEN), 5 ml of 10 mM HEPES, and 5 ml of penicillin (100 U/ml)-streptomycin (100 $\mu\text{g}/\text{ml}$)) was

aspirated from the plate. The cells were washed once with $1 \times$ PBS (1 ml), and then 1.6 ml of a new medium was added ((1)).

In the meantime, plasmid DNA was added to a 15-ml tube and then adjusted to be a total of 100 μ l using a buffer EC. An Enhancer (QIAGEN, attached to an Effectene transfection reagent kit) was added to the solution. The solution was agitated using a Vortex mixer for 1 second, left to stand at room temperature for 2 to 5 minutes, and then spun down. Next, an Effectene transfection reagent was added to the solution. The solution was vortexed for 10 seconds, and then left to stand at room temperature for 5 to 10 minutes. 600 μ l of a medium was added to the solution, and then pipetting was carried out ((2)).

The pipetted solution (2) was added to the solution (1) above, and then the mixture was cultured at 37°C for 48 hours. When selection was carried out using a drug, the drug was added 48 hours after transfection.

Furthermore, at 48 hours after transfection, expression efficiency was compared by FACS. Specifically, cells at 48 hours after transfection were washed twice with PBS, 2 ml of PBS-0.5 mM EDTA was added thereto, and then the cells were cultured at 37°C in 5% CO_2 , so that the cells were released. When the cells were released, 2 ml of a FACS buffer (9.8 g of HBSS (Hanks' Balanced Salt Solution, NISSUI PHARMACEUTICAL CO., LTD.) was dissolved in Milli-Q, and then to which 0.35 g of NaHCO_3 , 10 ml of 10% NaN_3 , and 5 ml of 20% BSA/ NaN_3 solution were added, followed by adjustment of the solution to 1 liter) was added. The solution was transferred into a 15-ml tube, and then centrifuged at $190 \times g$ for 10 minutes. The supernatant was discarded. Furthermore, the cells were washed once with 2 ml of a FACS buffer, the number of cells was determined, the solution was centrifuged at $190 \times g$ for 10 minutes, and then the supernatant was discarded.

The solution was diluted in a FACS buffer to achieve 8×10^6 cells/ml, and then the diluted solution was transferred into a FACS tube. 3 $\mu\text{g/ml}$ propidium iodide (SIGMA) was added in an amount half that of the diluted solution.

containing the cells, and then dead cells were stained. The cells were analyzed by CellQuest (Becton-Dickinson Immunocytometry Systems) using FACS Calibur. Viable cells were selected based on forward scattered light, lateral scattered light, and staining with propidium iodide (SIGMA). Thus, information
5 on 10000 viable cells was collected and analyzed. In addition, fluorescence of GFP (green fluorescence protein) of introduced pIRES-EGFP (CLONTECH) was detected and analyzed at this time.

As a result, it was revealed that the best efficiency of transfection was 3.65% when the amount of a reagent containing 0.8 μ g of DNA, 6.4 μ l of an
10 Enhancer, 8 μ l of an Effectene transfection reagent, and 99.5 μ l of a buffer EC was used.

(1-2) Examination of efficiency using LipofectamineTM 2000 reagent

Expression efficiency was examined for an LipofectamineTM 2000 reagent
15 (Invitrogen) using a pIRES-EGFP (CLONTECH, 4 μ g/minute) with a concentration of 0.526 μ g/ μ l.

Specifically, 4×10^5 cells were inoculated on a 6-well plate (FALCON 3046) on the day before transfection, and then cultured overnight at 37°C in 5% CO₂. The cells were grown to be 90% to 95% confluent on that day.

20 In the meantime, 4 μ g of plasmid DNA was diluted in 250 μ l of an Opti-MEM (attached within a LipofectamineTM 2000 reagent kit, Invitrogen) ((1)). 10 μ l of an LipofectamineTM 2000 reagent was diluted in 250 μ l of an Opti-MEM, and then cultured at room temperature for 5 minutes ((2)). DNA-LipofectamineTM 2000 reagent complexes were formed by mixing solution
25 (1) and solution (2) and then subjecting the resulting solution to static culture at room temperature for 20 minutes. The complexes were added to the cells, and then cultured at 37°C in 5% CO₂ for 24 hours.

24 hours after transfection, media were exchanged with fresh media, followed by another 24 hours of culture. When selection was carried out using a

drug, the drug was added at 48 hours after transfection.

Furthermore, at 48 hours after transfection, FACS analysis was carried out in a manner similar to that in (1-1) above.

As a result, the transfection efficiency was 8.20%. Therefore, it was
5 determined to carry out the following transfection using the LipofectamineTM 2000 reagent (Invitrogen).

(2) Expression of ERGIC random library

In this example, the ERGIC random libraries constructed in Example 6
10 were transfected into MDCK cells using an LipofectamineTM 2000 reagent (Invitrogen). At this time, the ERGIC random libraries linearized by restriction enzyme treatment were transfected.

All the ERGIC random libraries (2×10^5) constructed in Example 6 were subjected to restriction enzyme treatment with *Sca* I, and then purified using a
15 QIAquick Gel Extraction Kit (QIAGEN). In addition, the ERGIC random library used herein was prepared by mixing colonies so as to contain all the colonies at the same ratio based on a calculation (in the case of plasmids obtained by collecting 500 colonies and plasmids obtained by collecting 5000 colonies, the concentrations thereof were each measured and then the latter plasmids were used
20 such that the amount of DNA thereof was 10 times greater than that of the former plasmids). After purification, each concentration was measured using a spectrophotometer (JASCO, V-550).

4×10^5 MDCK cells were inoculated on a 6-well plate (FALCON, 3046) on the day before transfection, and then cultured overnight at 37°C in 5% CO₂.
25 The ERGIC random library (which had been cut with *Sca* I) was transfected into the above cells using 4 µg of a LipofectamineTM 2000 reagent (Invitrogen) per well, and then the cells were cultured for 24 hours at 37°C in 5% CO₂.

24 hours after transfection, media were exchanged with fresh media, followed by another 24 hours of culture at 37°C in 5% CO₂.

48 hours after transfection, media were exchanged with media containing 1.5 mg/ml G418, and then selection was initiated. After the start of selection, the cells were observed once a day, so as to confirm how the selection had proceeded.

5 10 days after the initiation of selection, cells that had grown in media containing 1.5 mg/ml G418 were treated with trypsin-EDTA (SIGMA) and then released from the plate as cells for which transfection had been confirmed. The number of cells was then counted.

10 10 days after addition of G418, the entire plate surface was coated with the cells. When the number of the cells was calculated, 9.5×10^6 cells were found to be present on each 6-well plate. Expression of mutated ERGIC-53 was confirmed by the Western blotting method (Example 8) and the indirect fluorescent antibody method (Example 9) using some of the cells in the following examples.

15 [Example 8] Confirmation of expression using the Western blotting method

Whether or not the ERGIC random libraries were expressed precisely in MDCK cells obtained by transfection into the MDCK cells and selection using
20 G418 in the above Example 7 was confirmed using the Western blotting method. In addition, untransfected MDCK cells were used as a control.

Some of cells on day 10 after selection using G418 in Example 7 were transferred into a 24-well plate (FALCON, 3047), and then cultured at 37°C in 5% CO₂ until the cells filled each well. In addition, MDCK cells used as a control
25 were also inoculated on a 24-well plate (FALCON, 3047) and then cultured similarly.

When the cells filled each well, 50 µl of trypsin-EDTA (SIGMA) was added thereto and the resultant was then cultured at 37°C in 5% CO₂ for approximately 20 minutes so as to release the cells. 500 µl of a medium was

added to the cells released from the plate, centrifugation was carried out at 1000 rpm for 5 minutes, and then the supernatant was discarded. The remained pellet was washed 2 to 3 times with $1 \times$ PBS.

The washed pellet of the cells was suspended in 50 μ l of $1 \times$ PBS. 25 μ l of a $2 \times$ SDS solubilization buffer (reduction) was added to the suspension, followed by 5 minutes of heat treatment at 100 °C and electrophoresis using 12.5% polyacrylamide gel at 200 V for 45 minutes. In addition, proteins molecular weight marker "Daiichi" III (Daiichi Pure Chemicals) was used as a marker.

By the use of the Western blotting method, the proteins electrophoresed as described above were transferred to PVDF membranes (ImmobilonTM Transfer Membranes, Millipore) at 100V for 60 minutes. After transfer, marker portions were cut out, stained with CBB, and then destained. The remaining membranes were immersed in blocking solutions, and then left to stand at 4°C overnight (the solutions were shaken so that the membranes were uniformly immersed in the blocking solutions).

After blocking, each membrane was put in a Hybri-Bag Soft (COSMO BIO), and then allowed to react with antibodies. As a primary antibody, a solution (4.5 ml) prepared by diluting an anti-FLAG antibody (m2Ab, IBI) using a blocking solution at a concentration of 1 μ g/ml was used and then allowed to react at room temperature for 2 hours. Subsequently, the membrane was washed 3 times (5 minutes each) with a washing buffer, and then allowed to react with a secondary antibody. As the secondary antibody, a solution (4.5 ml) prepared by diluting a goat anti-mouse Ig alkaline phosphatase conjugate (BIORAD) at 3000-fold dilution using a blocking solution (5% skim milk was adjusted using TBS-Tween20) was used and allowed to react at room temperature for 30 minutes. Subsequently, the membrane was washed 3 times in total (15 minutes, 5 minutes, and 5 minutes of washing) with a washing buffer. After washing, the membrane was immersed in a chromogenic substrate solution and then left to stand until

bands appeared on the membrane. The chromogenic substrate solution was prepared by adding 33 μ l of an NBT stock solution (50 mg of NBT was dissolved in 1 ml of 70% DMF (N, N-dimethylformamide) and then stored at -20°C) and 34 μ l of a BCIP stock solution (25 mg of BCIP was dissolved in 1 ml of 50% DMF and then stored at -20°C) to 5 ml of an alkaline phosphatase substrate buffer containing 100 mM Tris-HCl (pH 9.5), 100 mM NaCl, and 5 mM MgCl_2 in Milli-Q. At a time to stop color development, the membrane was washed in tap water and then air-dried.

The ERGIC random libraries were transfected into MDCK cells, selected with G418 for 10 days, and then subjected to Western blotting, so that expression was confirmed. Compared with the mock transfected MDCK cells, a band that had not been observed in the case of the mock was observed between 66 kDa and 42 kDa molecular weight markers. As indicated in the name ERGIC-53, the molecular weight thereof was 53 kDa and almost in accordance with the position of the band. Hence, it was confirmed that the ERGIC random libraries were expressed in MDCK cells.

[Example 9] Confirmation of expression using indirect fluorescent antibody method

In the above Example 8, it was confirmed by Western blotting that the MDCK cells into which the ERGIC random libraries had been transfected, and selected with G418 for 10 days, expressed the ERGIC random libraries. Next, through observation using the indirect fluorescent antibody method, the percentage of the transfected cells expressing mutated ERGIC-53 was confirmed.

The indirect fluorescent antibody method involves allowing an unlabeled antibody to react with an antigen, binding a fluorescence-labeled secondary antibody to a primary antibody, and then tracing the antigen. A primary antibody functions as an antigen for a secondary antibody, and a fluorescence-labeled immunoglobulin antibody is used as a secondary antibody, whereby the presence or the distribution

of an antigen substance of a tissue or cells can be analyzed with good sensitivity. Since the library-composing ERGIC was FLAG-tagged, observation was carried out with a fluorescence microscope using an anti-FLAG antibody (m2Ab, IBI) as a primary antibody and a goat anti-mouse IgG₁-FITC conjugate (Molecular Probes) as a secondary antibody. In addition, untransfected MDCK cells were used as a negative control, and VIP36-FLAG clone 8 (cell line for which constant expression of FLAG-tagged VIP36 had been confirmed) was used as a positive control.

A cover glass (MATSUNAMI) subjected to high-pressure heat sterilization was laid onto a 6-well plate (FALCON, 3046), upon which some (2×10^5) of the cells after 10 days of selection with G418 in Example 7 were inoculated, and then the resultant was cultured at 37°C in 5% CO₂ until 90 % of the wells were covered with the cells. In addition, untransfected MDCK cells and VIP36-FLAG clone 8 used as controls were also cultured similarly.

On the day of sample preparation, it was confirmed that the cover glass was covered with the cells to some extent. After the media were discarded, the cells were washed once with PBS, to which 1 ml of 4% paraformaldehyde/PBS was added, and then treated at room temperature for 60 minutes, thereby immobilizing them. Subsequently, the cells were washed once with PBS.

The cell membranes were permeabilized by treatment using 0.1% TritonX-100/PBS (1 ml) for 30 minutes at room temperature, followed by 3 times of washing (5 minutes each) with PBS.

Blocking was carried out using a blocking solution (1 ml) at room temperature for 15 minutes, followed by 3 times of washing (5 minutes each) with PBS.

200 µl of the anti-FLAG antibody (m2Ab, IBI) diluted at a concentration of 2 µg/ml using a blocking solution was added onto each cover glass, and then allowed to react at room temperature for 60 minutes, followed by 3 times of washing (10 minutes each) with PBS.

Blocking was carried out again using a blocking solution (1 ml) at room temperature for 15 minutes, followed by 3 times of washing (5 minutes each) with PBS.

200 μ l of the anti-mouse IgG₁-FITC (CBL1000F) diluted at a concentration of 2 μ g/ml using a blocking solution was added onto each cover glass, light was shielded, and then reaction was carried out at room temperature for 60 minutes, followed by 3 times of washing (10 minutes each) with PBS.

3 μ l of DAPI (Molecular Probes) and 3 μ l of a slow fade (Molecular Probes) solution A were dropped onto a slide glass (MATSUNAMI). A cover glass was placed on each slide glass so that its cell-adhered face became an undersurface, and then sealed-in using manicure, so as to prepare each sample. Light was shielded for the samples and then they were stored at 4°C.

The prepared samples were observed by a fluorescence microscope (OLYMPUS, BX52). First, negative control MDCK cells were observed, and then positive control VIP36-FLAG clone 8 was observed, so as to confirm whether antibody reaction had been carried out well. Next, the MDCK cells into which the ERGIC random libraries had been transfected and which were then caused to express the libraries were observed. Specifically, several positions were randomly selected from both (left and right) sides of the samples, and then the samples were recorded. The total number of the cells and the number of FITC-positive cells filmed on the photograph were counted. The number of the cells observed to show expression was quantified.

As results, photographs of the samples for a fluorescence microscope are shown in Fig. 9A to C. Fig. 9A to C show overlay of phase contrast images of the cells (gray) and images of the cells stained with FITC (green). A photograph of the negative control MDCK cells is shown in Fig. 9A and that of the positive control VIP36-FLAG clone 8 is shown in Fig. 9B. In the case of the positive control, each cell emitted very strong green; that is, staining with FITC, the secondary antibody, was observed.

Fig. 9C shows MDCK cells observed after transfection of the ERGIC random libraries and 10 days of selection with 1.5 mg/ml G418. In this figure, 1 or 2 cells per photograph can be seen to have emitted very strong green, indicating strong staining with FITC, the secondary antibody. The total number of the cells filmed on 8 photographs was 387, of which the number of cells strongly stained with FITC was 12. Among samples observed in this time, specifically, it can be said that 12 cells out of 387 cells (3.1%) were cells expressing the libraries strongly.

[Example 10] Screening by MACS based on sugar-binding specificity of plant lectin and FACS analysis for cell expressing ERGIC random library

In this example, the sugar-binding specificities of plant lectins were focused on, and cells expressing the ERGIC random libraries were screened by MACS. Specifically, the cells expressing the ERGIC random libraries were primarily labeled with several types of biotinylated Leguminosae lectins, magnetically labeled with streptavidin microbeads, and then screened using a magnetic cell sorting system (Magnetic Cell Sorting and Separation of Biomolecules, hereinafter abbreviated as MACS). Subsequently, after FACS selection, cells were analyzed by FACS.

(1) MACS screening for cell expressing ERGIC random library

As biotinylated lectins, Biotin-Lectin sets I and II (Honen Corporation) were used. ConA, BPA, ABA, WGA, SBA, SSA, DBA, DSA, RCA120, LCA, PNA, PHA-L₄, PHA-E₄, Lotus, UEA-I, and MAM (1 mg/ml each) were each diluted with PBS, adjusted to 10 µg/ml, and then sterilized with a 0.45 µm filter (MILLEXOR-HV).

2 days before MACS screening, 4×10^5 cells were inoculated on sixteen 10-cm dishes, and then cultured at 37°C in 5% CO₂.

On the day of MACS screening, the cells were washed twice with PBS, to

which 5 ml of PBS-0.5 mM EDTA was added, and then the cells were incubated at 37°C in 5% CO₂, so as to harvest the cells. Centrifugation was carried out at 190 × g for 5 minutes, and then the supernatant was discarded.

Each type of lectin (10 µg/ml, 2 ml) was added to the cells for reaction to occur on ice for 30 minutes, centrifugation was carried out for 10 minutes at 30 × g, and then the supernatant was removed. After washing with 300 µl of a labeling buffer (prepared using PBS (pH 7.2) and 2 mM EDTA with Milli-Q, followed by filter sterilization), centrifugation was carried out at 300 × g for 10 minutes, and then the supernatant was removed.

The cells were suspended in 90 µl of a labeling buffer, to which 10 µl of streptavidin MicroBeads (Miltenyi Biotec GmbH) was added, followed by 15 minutes of reaction at 6°C to 12°C. After washing with 500 µl of a separation buffer (prepared using PBS (pH 7.2), 2 mM EDTA, and 0.5% BSA with Milli-Q water, followed by filter sterilization), centrifugation was carried out at 300 × g for 10 minutes, the supernatant was removed, and then suspension was carried out with 500 µl of a separation buffer.

A MS separation column (Miltenyi Biotec GmbH) was set together with a Mini MACS (Miltenyi Biotec GmbH) magnet, and then 500 µl of a separation buffer was poured into the column. Subsequently, the above cell suspension was applied to the MS separation column, and then the cells eluting out from the column were collected as negative cells (flow-through). 500 µl of a separation buffer was applied 3 times to the MS separation column, and then the cells eluting out from the column were also collected as negative cells (flow-through).

The column was removed from the magnet, and then 1 ml of a separation buffer was applied to the column. The column content was pushed out using the plunger of a syringe and then the cells eluting out from the column were collected as positive cells.

After the obtained positive and negative cells (flow-through) were centrifuged at 300 × g for 10 minutes, the supernatant was removed. The pellet

was suspended in an appropriate amount of a medium (which had already been supplemented with 1.0 mg/ml G418). The suspension was inoculated on plates with an appropriate size (a 6 cm dish or a 10 cm dish), and then the cells were cultured again.

5 This experiment was performed with intent to screen for cells based on the types of carbohydrate moieties (sugar chains) added to the membrane proteins on the cell surfaces utilizing the sugar-binding specificities of lectins. The cells labeled with biotinylated lectins and applied to MACS were all divided into negative cells (flow-through) and positive cells. Since it was thought that the
10 cells immediately after MACS had been severely damaged, the number of the cells was counted on the day after MACS screening, and then the ratio at which the cells were divided was confirmed. The results are shown in the following Table 4. However, both negative (flow-through) and positive cells labeled with biotin labeled RCA120 and then subjected to MACS died.

Table 4

Lectin name	Negative (flow-through)	Positive
ConA	80%	20%
DBA	88%	12%
LCA	90%	10%
PHA-E ₄	85%	15%
PNA	95%	5%
UEA-I	80%	20%
WGA	86%	14%
ABA	75%	25%
DSA	70%	30%
Lotus	93%	7%
MAM	20%	80%
PHA-L ₄	82%	18%
SBA	85%	15%
SSA	60%	40%
BPA	90%	10%

As is understood from Table 4 above, most cells selected by MACS in this

example were collected as flow-through. Differences depending on the lectins used were not clearly observed.

Among the cell fractions obtained in this time, negative cells (flow-through) were designated (-), cells that had passed through the column after being recognized as positive cells and selected by MACS were designated ConA (-), and cells finally collected as positive cells were designated ConA (+). Regarding other lectins, similar notation was employed. A total of 30 types of these cells were subjected to FACS analysis in the following experiments.

(2) FACS analysis

30 types of cells that had been selected by MACS in (1) above and then grown successfully were analyzed by FACS. Specifically, the cells were allowed to react with 15 types of biotinylated lectins as primary antibodies and FITC-labeled streptavidin (PIERCE) as a secondary antibody, and then changes in fluorescence intensity were observed using FACS. In addition, untransfected MDCK cells were used as a control.

On the day before FACS, 2×10^5 cells to be analyzed were inoculated on a 6-cm plate. On the day of FACS, each type of cell was washed twice with PBS, to which 2.5 ml of PBS-0.5 mM EDTA was added, and then the cells were cultured at 37°C in 5% CO₂, so as to release the cells. When the cells were released, 2.5 ml of a FACS buffer (prepared by dissolving 9.8 g of HBSS (NISSUI PHARMACEUTICAL CO., LTD.) in Milli-Q, and then to which 0.35 g of NaHCO₃, 10 ml of 10% NaN₃, and 5 ml of 20% BSA/NaN₃ solution were added, followed by adjustment of the solution to 1 liter) was added. The solution was transferred into a 15-ml tube, centrifugation was carried out at 1000 rpm for 10 minutes, and then the supernatant was discarded. Furthermore, the cells were washed once with 5 ml of a FACS buffer, the number of the cells was determined, centrifugation was carried out at $190 \times g$ for 10 minutes, and then the supernatant was discarded.

The cells were diluted with a FACS buffer to a concentration of $8 \times 10^6/\text{ml}$ ($4 \times 10^5/50 \mu\text{l}$). The diluted solution was transferred in amount of $50 \mu\text{l}$ into a 96-well U-bottom plate (3077, FALCON). $50 \mu\text{l}$ of $10 \mu\text{g}/\text{ml}$ biotinylated lectin was added as a primary antibody to each well. The solution was gently stirred, and then allowed to react on ice for 30 minutes.

$100 \mu\text{l}$ of a FACS buffer was added, the solution was centrifuged at $580 \times g$ for 3 minutes, and then the supernatant was discarded. The pellet was applied to Vortex mixer to disassemble it. A similar washing operation was further repeated twice (in addition, washing was carried out by adding $200 \mu\text{l}$ of a FACS buffer at each time).

$50 \mu\text{l}$ of streptavidin FITC (diluted with a FACS buffer to $20 \mu\text{g}/\text{ml}$) was added as a secondary antibody. The solution was lightly stirred, light was shielded, and then the solution was allowed to react on ice for 20 to 30 minutes.

$150 \mu\text{l}$ of a FACS buffer was added, the solution was centrifuged at $580 \times g$ for 3 minutes, and then the supernatant was discarded. A similar washing operation was repeated once more.

$200 \mu\text{l}$ of a FACS buffer was added to each well. After pipetting, the solution was transferred into a FACS tube. $100 \mu\text{l}$ of $3 \mu\text{g}/\text{ml}$ propidium iodide (SIGMA) was added, and then dead cells were stained. The cells were analyzed by CellQuest (Becton-Dickinson Immunocytometry Systems) using FACSCalibur. Viable cells were selected based on forward scattered light, lateral scattered light, and staining with propidium iodide (SIGMA). Information on 10,000 viable cells was collected and analyzed.

In the ERGIC random library, random mutations had been introduced into amino acids corresponding to the putative carbohydrate-binding domain of ERGIC-53. ERGIC-53 is a molecule that exists in transport vesicles moving between the endoplasmic reticulum (ER) and the cis Golgi and selectively transports (because of the sugar-binding specificity of carbohydrate recognition domain, it binds to mannose in a Ca^{2+} -dependent manner) glycoproteins. Hence,

it is considered that through introduction of random mutations into a carbohydrate recognition domain or a carbohydrate-binding domain, sugar-binding specificities differing from the original specificity of ERGIC-53 are generated in the ERGIC random library, and mutated ERGIC-53 will bind to glycoproteins having various carbohydrate moieties, so that the carbohydrate moiety-types of glycoproteins transported onto the cell membrane surface will be varied. In MACS carried out in Example 10, cells were sorted based on the sugar-binding specificities (see the following Table 5) of various biotinylated lectins used herein, and then collected as separate fractions. Generally, when a lectin binds to a carbohydrate moiety, it recognizes a size of around that of a trisaccharide, and identifies the three-dimensional structure. Analysis using FACS reveals what type of carbohydrate moiety is present on the cell surface at what ratio by staining with biotinylated lectins.

Table 5

Lectin name	Origin	Specificity
ConA	<i>Canavalia ensiformis</i> Jack bean	α -D-Man α -D-Glc
DBA	<i>Dolichos biflorus</i>	D-GalNAc
LCA	<i>Lens culinaris</i>	α -D-Glc α -D-Man
PHA-E ₄	<i>Phaseolus Vulgaris</i>	D-GalNAc
PNA	Peanut (<i>Arachis hypogaea</i>)	D-Gal Gal β 1-3GalNAc
UEA-I	<i>Ulex europaeus</i>	α -L-Fuc
WGA	Wheat Germ	D-GlcNAc
ABA	<i>Agaricus bisporus</i>	β -D-Gal
DSA	<i>Datura stramonium</i> (foreign species)	β -D-GlcNAc Gal β 1-4GalNAc
Lotus	<i>Lotus Itetragonolous</i>	α -L-Fuc
MAM	<i>Maackia amurensis</i>	SA α 2-3Gal
PHA-L ₄	<i>Phaseolus Vulgaris</i>	D-GalNAc
SBA	Soybean	D-GalNAc

SSA	<i>Sambucus sieboldiana</i>	SA α 2-6Gal/GalNAc
BPA	<i>Bauhinia purpurea</i>	D-GalNAc>D-Gal

The results of FACS analysis are shown in Fig. 10. In Fig. 10, cells following MACS screening and control cells (wild type MDCK cells) were compared, and then the difference in average fluorescence intensity was observed. In Fig. 10, a black line indicates the control MDCK cells, a red line indicates the (-) fraction following MACS, and a green line indicates the (+) fraction. Those showing average fluorescence intensity of the (+) fraction and that of the (-) fraction higher than that of the control were only the cells obtained by primary labeling with PNA and ABA, followed by MACS screening. Specifically, it can be said that among ERGIC random library-expressing cells, cells presenting carbohydrate moieties specifically bound to PNA lectin on the cell surfaces were selected by MACS.

SBA, DBA, PHA-E₄, PHA-L₄, and BPA are all lectins specifically binding to D-GalNAc. As shown in the FACS result in Fig. 10, in the case of all lectins, almost no differences were observed in average fluorescence intensity between the control and (+) and (-) fractions.

[Example 11] Analysis of cell specific to PNA lectin

In this example, through further screening by MACS of the PNA (+) cells obtained in Example 10, we tried to enrich cells presenting more carbohydrate moieties specifically bound to PNA lectin on the cell surfaces. Furthermore, analysis was carried out by FACS and lectin staining using the Western blotting method.

(1) MACS separation and FACS analysis of PNA(+)

Screening of the PNA(+) cells obtained in Example 10 was carried out by MACS, and then the cells were analyzed by FACS. In addition, as a control for FACS, untransfected MDCK cells were used.

(1-1) Screening for PNA (+) by MACS

4×10^5 cells (PNA(+)) were inoculated on a 10 cm-dish (FALCON, 3003) and then cultured at 37°C in 5% CO₂ for 2 days.

5 The cells were washed twice with PBS, to which 5 ml of PBS-0.5 mM EDTA was then added, so as to harvest the cells. Centrifugation was carried out at 190 × g for 5 minutes, and then the supernatant was discarded.

10 Biotinylated PNA lectin (10 µg/ml, 2 ml) was added to the cells for binding to occur on ice for 30 minutes. Centrifugation was carried out at 300 × g for 10 minutes, and then the supernatant was removed. After washing with 300 µl of a labeling buffer, centrifugation was carried out at 300 × g for 10 minutes, and then the supernatant was removed.

15 The cells were suspended in 90 µl of a labeling buffer, to which 10 µl of streptavidin MicroBeads (Miltenyi Biotec GmbH) was then added, followed by 15 minutes of reaction at 6°C to 12°C. After washing with 500 µl of a separation buffer, 10 minutes of centrifugation at 300 × g, and then removal of the supernatant, the product was suspended in 500 µl of a separation buffer.

20 A MS separation column (Miltenyi Biotec GmbH) was set together with a MiniMACS (Miltenyi Biotec GmbH) magnet, and then 500 µl of a separation buffer was applied to the column. Subsequently, the above cell suspension was applied to the MS separation column, and then the cells eluting out from the column were collected as negative cells (flow-through). 500 µl of a separation buffer was applied 3 times to the MS separation column, and then the cells eluting out from the column were also collected as negative cells (flow-through).

25 The column was removed from the magnet, and then 1 ml of a separation buffer was applied to the column. The column content was pushed out using the plunger of a syringe and then the cells eluting out from the column were collected as positive cells.

After the obtained positive and negative cells (flow-through) were centrifuged at 300 × g for 10 minutes, the supernatant was removed. The pellet

was suspended in an appropriate amount of a medium (that had already been supplemented with 1.0 mg/ml G418). The suspension was inoculated on dishes with an appropriate size (a 6 cm dish or a 10 cm dish), and then the cells were cultured again.

5 As a result, 65% of the collected cells were found to be negative cells (flow-through) and 35% of the collected cells were found to be positive cells. Hereinafter, negative cells collected by applying PNA(+) to MACS are referred to as PNA2(-), and positive cells collected by the same are referred to as PNA2(+). At the 1st round of MACS (Example 10), 95% of the cells were PNA(-) and 5% of
10 the same were PNA (+). At the 2nd round of MACS, the percentage of the cells collected as the (+) fraction increased.

(1-2) FACS analysis

15 On the day before FACS, 2×10^5 cells to be analyzed were plated on a 6-cm dish (FALCON, 3002). On the day of FACS, each type of cell was washed twice with PBS, to which 5 ml of PBS-0.5 mM EDTA was then added, and then the cells were cultured at 37°C in 5% CO₂, so as to release the cells. When the cells were released, 5 ml of a FACS buffer was added. The solution was transferred into a 15-ml tube, centrifugation was carried out at 190×g for 10
20 minutes, and then the supernatant was discarded. Furthermore, the cells were washed once with 5 ml of a FACS buffer, the number of the cells was determined, centrifugation was carried out at 190 × g for 10 minutes, and then the supernatant was discarded.

25 The cells were diluted with a FACS buffer to a concentration of 8×10^6 /ml (4×10^5 /50 μl). The diluted solution was transferred in amount of 50 μl into a 96-well U-bottom plate (3077, FALCON). 50 μl of 10 μg/ml biotinylated PNA lectin was added as a primary antibody to each well. The solution was gently stirred, and then allowed to react on ice for 30 minutes.

100 μl of a FACS buffer was added, the solution was centrifuged at 580 ×

g for 3 minutes, and then the supernatant was discarded. The pellet was applied to Vortex mixer to disassemble it. A similar washing operation was further repeated twice.

5 50 μ l of streptavidin FITC (diluted with a FACS buffer to 20 μ g/ml) was added as a secondary antibody. The solution was slightly stirred, light was shielded, and then the solution was allowed to react on ice for 20 to 30 minutes.

10 150 μ l of a FACS buffer was added, the solution was centrifuged at 580 $\times$ g for 3 minutes, and then the supernatant was discarded. The pellet was applied to Vortex mixer to disassemble it. Similar washing operation was repeated once more (in addition, washing was carried out by adding 200 μ l of a FACS buffer at each time).

15 200 μ l of a FACS buffer was added to each well. After pipetting, the solution was transferred into a FACS tube. 100 μ l of 3 μ g/ml propidium iodide (SIGMA) was added, and then dead cells were stained. The cells were analyzed by CellQuest (Becton-Dickinson Immunocytometry Systems) using FACSCalibur. Viable cells were selected based on forward scattered light, lateral scattered light, and staining with propidium iodide (SIGMA). Information on 10,000 viable cells was collected and analyzed.

20 The results are shown in Fig. 11. PNA(-), PNA(+), and PNA2(+) were compared. As a control, untransfected MDCK cells were used. As shown in Fig. 11, the average fluorescence intensity of PNA2(+) was higher than that of PNA(+), suggesting that cells presenting more carbohydrate moieties (sugar chains) specifically bound to PNA on the cell surfaces were collected in PNA2(+).

25 (2) Lectin staining using the Western blotting method

Based on the result of (1) above, it was considered that PNA2(+) was cells group having more carbohydrate moieties specifically bound to the PNA lectin on the cell surfaces compared with the case of PNA(+) or PNA(-). Hence, in this example, lectin staining was carried out using the PNA lectin by the Western

blotting method, and then differences in the degree of staining among PNA(-), PNA(+), and PNA2(+) were observed. Furthermore, through the use of 4 types of lectins (ConA, MAM, PHA-E₄, and PHA-L₄), lectin staining was carried out by the Western blotting method using lectins having different sugar-binding specificities from that of PNA, followed by comparison. In addition, as a control, untransfected MDCK cells were used.

Cells were inoculated on a 6-well plate (FALCON, 3046), and then cultured at 37°C in 5% CO₂ until the cells filled about 90% of each well.

When the cells had sufficiently grown, 500 µl of cells lysis buffer (10 mM EDTA, 0.2% Triton X-100, 1 mM PMSF, and 1 µg/ml leupeptin were adjusted using PBS) was added to the cells, and then the solution was placed on ice for 1 to 1.5 hours so as to lyse the cells.

After treatment with the cell lysis buffer, the cell lysates were subjected to protein quantitative determination using a BCProteins assay kit (PIERCE). The cell lysates were diluted using PBS at a concentration that was the same as the lowest concentration. 10 µl of each cell lysate diluted at the lowest protein concentration was transferred into a 1.5 ml-tube, to which 2 µl of a 6 × SDS solubilization buffer (reduction) was then added, followed by 5 minutes of heat treatment at 100°C. Subsequently, electrophoresis was carried out at 200 V for 45 minutes using 12.5% acrylamide gel.

By the use of the Western blotting method, the above-electrophoresed proteins were transferred to PVDF membranes (ImmobilonTM Transfer Membranes, Millipore) at 100 V for 60 minutes. After transfer, marker portions were cut out, stained with CBB, and then destained. The remaining membranes were immersed in blocking solutions and left to stand at 4°C overnight (the solutions were shaken so that the membranes were uniformly immersed in the antibody-containing blocking solutions).

After blocking, each membrane was put in a Hybri-Bag Soft (COSMO BIO), and then allowed to react with antibodies. As a primary antibody, a

solution (4.5 ml) prepared by diluting a biotinylated lectin with a blocking solution to a concentration of 1 μ g/ml was used, and allowed to react at room temperature for 2 hours. Subsequently, the membrane was washed 3 times (5 minutes each) with a washing buffer, and then allowed to react with a secondary antibody. As the secondary antibody, a solution (4.5 ml) prepared by diluting streptavidin alkaline phosphatase with a blocking solution to a concentration of 1 μ g/ml was used and allowed to react at room temperature for 30 minutes. Subsequently, the membrane was washed 3 times in total (15 minutes, 5 minutes, and 5 minutes of washing) with a washing buffer. After washing, the membrane was immersed in a chromogenic substrate solution and then left to stand until bands appeared on the membrane. At a time to stop color development, the membrane was washed in tap water and then air-dried.

The results are shown in Fig. 12. In the results of Western blotting using PNA, band thickness was observed in the descending order of PNA2(+) > PNA(+) > PNA(-) > control. However, no significant differences were observed, suggesting that the specificities to PNA were at the same level for all the cell fractions analyzed in this time. Furthermore, in the result of Western blotting using ConA, PHA-E₄, and PHA-L₄, no large differences were observed between the control and PNA(-), PNA(+), or PNA2(+) in terms of the degree of staining. In the results of Western blotting using MAM, a slight difference in band thickness was observed in the descending order of the control > PNA(-) > PNA(+) > PNA2(+).

Next, when the degree of staining with each lectin was compared, thickness as a result of staining was observed in the descending order of ConA > PHA-E₄, PHA-L₄ > PNA > MAM in every case regarding the control, PNA(-), PNA(+), and PNA2(+).

Here, the sugar-binding specificity of each lectin used in Western blotting in this experiment is explained. ConA is a lectin showing affinity for α -D-Man and α -D-Glc and binds to biantennary complex-type and high mannose-type, and

hybrid-type sugar chains. Furthermore, both PHA-L₄ and PHA-E₄ show affinity for D-GlcNAc and bind to complex-type carbohydrate moiety among asparagine-binding-type carbohydrate moieties. PNA has affinity for D-Gal and is a lectin specific to a Ser/Thr-type carbohydrate moiety so that it particularly strongly binds to Gal β 1-3GalNAc. Moreover, MAM has specificity to SA α 2-3Gal and is a lectin specific to sialic acid so that it binds strongly to SA α 2-3Gal β 1-3GalNAc. In terms of the biosynthetic process of oligosaccharides, the high mannose-type oligosaccharides are added in the cis Golgi (ER), the complex-type oligosaccharides are processed in the medial and trans Golgi, and the Ser/Thr linked oligosaccharides are added in the trans Golgi. Carbohydrate moieties having sialic acids are added in the final processing step in the trans Golgi. There may be correlation between these facts and the results of Western blotting in this experiment wherein the band thickness was detected in the descending order of ConA > PHA-E₄, PHA-L₄ > PNA > MAM. Specifically, Western blotting using lectins specific to carbohydrate moieties to be added at earlier stages in oligosaccharide processing resulted in thicker staining. This suggests the possibility that most of cellular glycoproteins were being biosynthesized and that differences among glycoproteins expressed on the cell surfaces were relatively small.

20

(3) Glycosylation in the trans Golgi

As a result of Western blotting carried out in (2) above, in the case of Western blotting using MAM and PNA, only slight differences were observed in intensity of band among each sample of the control, PNA(-), PNA(+), and PNA2(+). Hence, in this example, intensity of band resulting from Western blotting were quantitatively determined. It was considered that since intra- and extracellular proteins are lysed together and analyzed in Western blotting, intracellular immature glycoproteins were predominant, so that it is impossible to clearly observe differences between such intracellular glycoproteins and

membrane glycoproteins having binding specificity to PNA. Thus, analysis by flow cytometry was also carried out.

(3-1) Analysis using image analyzer

The membranes obtained by Western blotting in (2) above were quantitatively determined using an image analyzer (LAS-1000, FUJI PHOTO FILM), and then intensity of band was compared.

Analysis using the image analyzer involves finding the average value per unit area of a band to be quantitatively determined and comparing average values. The results are shown in the following Table 6.

Table 6

	PNA	MAM
Control	4554000	4792000
PNA(-)	4618000	4776000
PNA(+)	4638000	4750000
PNA2(+)	4747000	4714000

As shown in Table 6 above, in the case of Western blotting using PNA, intensity of band was observed in the ascending order of the control < PNA(-) < PNA(+) < PNA2(+) and in the case of Western blotting using MAM, the intensity of band was observed in the descending order of the control > PNA(-) > PNA(+) > PNA2(+). However, in each case, the difference was as subtle as approximately 1%.

(3-2) FACS analysis

Next, analysis focusing on membrane glycoproteins on cell surfaces was carried out using FACS. On the day before FACS, 2×10^5 cells to be analyzed (control MDCK cells, PNA(-), PNA(+), and PNA2(+)) were inoculated on a 6-cm dish (FALCON, 3002). On the day of FACS, each type of cell was washed twice with PBS, to which 5 ml of PBS-0.5 mM EDTA was then added, and then the cells were incubated at 37°C in 5% CO₂, so as to harvest the cells. When the cells

were released, 5 ml of a FACS buffer was added. The solution was transferred into a 15-ml tube, centrifugation was carried out at $190 \times g$ for 10 minutes, and then the supernatant was discarded. Furthermore, the cells were washed once with 5 ml of a FACS buffer, the number of the cells was determined, centrifugation was carried out at $190 \times g$ for 10 minutes, and then the supernatant was discarded.

The cells were diluted with a FACS buffer to a concentration of $8 \times 10^6/\text{ml}$ ($4 \times 10^5/50 \mu\text{l}$). The diluted solution was transferred in amount of 50 μl into a 96-well U-bottom plate (3077, FALCON). 50 μl of 10 $\mu\text{g}/\text{ml}$ biotinylated PNA lectin or MAM lectin was added as a primary antibody to each well. The solution was gently stirred, and then allowed to react on ice for 30 minutes.

100 μl of a FACS buffer was added, the solution was centrifuged at $580 \times g$ for 3 minutes, and then the supernatant was discarded. After a Kim towel was held to the pellet to remove water, the pellet was applied to Vortex mixer to disassemble it. A similar washing operation was further repeated twice.

50 μl of streptavidin FITC (diluted with a FACS buffer to 20 $\mu\text{g}/\text{ml}$) was added as a secondary antibody. The solution was lightly stirred, light was shielded, and then the solution was allowed to react on ice for 20 to 30 minutes.

150 μl of a FACS buffer was added, the solution was centrifuged at $580 \times g$ for 3 minutes, and then the supernatant was discarded. After a Kim towel was held to the pellet to remove water, the pellet was applied to Vortex mixer to disassemble it. A similar washing operation was repeated once more.

200 μl of a FACS buffer was added to each well. After pipetting, the solution was transferred into a FACS tube. 100 μl of 3 $\mu\text{g}/\text{ml}$ propidium iodide (SIGMA) was added, and then dead cells were stained. The cells were analyzed by CellQuest (Becton-Dickinson Immunocytometry Systems) using FACSCalibur. Viable cells were selected based on forward scattered light, lateral scattered light, and staining with propidium iodide (SIGMA). Information on 20,000 viable cells was collected and analyzed.

By the use of biotinylated lectin (MAM or PNA) as a primary antibody and streptavidin FITC as a secondary antibody, fluorescence intensity was measured for 4 cell fractions (control MDCK wild-type cells, PNA(-), PNA(+), and PNA2(+)) and the average values thereof were compared. The results are shown in Fig. 13. In Fig. 13, in the results of FACS using PNA as a primary antibody, the value of the average fluorescence intensity was observed in the ascending order of the control < PNA(-) < PNA(+) < PNA2(+). In the meantime, in the results of FACS using MAM as a primary antibody, the value of the average fluorescence intensity was observed in the descending order of the control > PNA(-) > PNA(+) > PNA2(+). Specifically, the results of FACS using MAM and the results of FACS using PNA showed an inverse correlation. Furthermore, the results were in accordance with the results of analysis of the degree of staining in Western blotting using an image analyzer. Here, in terms of oligosaccharide processing, the results are considered. To Ser/Thr linked oligosaccharides, carbohydrate moieties are added in the order of GalNAc-Ser/Thr → Galβ1-3GalNAc-Ser/Thr → SAα2-3Galβ1-3GalNAc-Ser/Thr. PNA specifically recognizes and binds to Galβ1-3GalNAc-Ser/Thr, but does not recognize at all when SA (sialic acid) is added thereto. On the other hand, MAM is a lectin that specifically recognizes and binds to SAα2-3Galβ1-3GalNAc-Ser/Thr, but does not recognize any sugar chains at a stage where a sialic acid has not yet been added thereto. When the above facts and the results shown in Fig. 13 are taken together, it is considered that cell fractions presenting more Galβ1-3GalNAc-Ser/Thr on the cell surfaces thereof were collected in PNA2(+).

25

In Examples 5 to 11 above, among 9 amino acids (DTFDNDGKK) corresponding to the putative carbohydrate-binding domain of ERGIC-53, random mutations were introduced into 7 amino acids (DXXXNXXXX; X denotes any amino acid) and then introduced into pRc-CMV2, the vector. Thus, ERGIC-53

random libraries were constructed, the libraries were transfected into MDCK cells, and then the cells were forced to express recombinant ERGIC-53. In this specification, the cells are referred to as "cells expressing ERGIC random libraries." After transfection, selection using G418 was carried out, and in order
5 to screen for cells expressing glycoproteins having various carbohydrate moieties on the cell surfaces thereof, the cells were primarily labeled using various biotinylated lectins, magnetically labeled with streptavidin MicroBeads, and then screening was carried out using the magnetic cell sorting system (MACS). As a result, MDCK cells reacting with several types of lectins could be separated; that
10 is, cells having specific lectin-binding activity (that is able to specifically recognize carbohydrate moieties) could be obtained.

[Example 12] Screening of mutated-VIP36-transfected cell using FACS and enrichment of cell expressing a glycoprotein with a modified carbohydrate
15 moiety

(1) Construction of mutated VIP36-expressing CHO cell library

CHO (Chinese hamster ovary cells) cells (provided by the Cell Resource Center for Biomedical Research, Tohoku University) were cultured in RPMI1640 supplemented with 10% fetal bovine serum (FBS) in the presence of 5% CO₂.
20 CHO cells cultured to be confluent were collected by trypsin/EDTA, diluted 10-fold, and then further cultured overnight. 12 µg of plasmids (linear) of the mutated VIP36 gene library constructed in Example 1 was used for transfection into 2.4×10^6 CHO cells according to a standard method using Lipofectamine 2000 (GIBCO). After the cells were cultured for 48 hours in RPMI1640
25 containing 10% FBS in the presence of 5% CO₂, the cells were cultured in the same culture medium containing 1.2 mg/ml G418 (CalbioChem) for 10 to 14 days. Thus, only cell lines constitutively expressing mutated VIP36 were selected.

(2) Screening for altered-VIP36-expressing cell by flow cytometry

The altered VIP36-expressing CHO cells prepared in (1) above were diluted to be 10% confluent in a 10 cm-dish, and then cultured. After 48 hours, the cells were released and collected using a phosphate buffer (pH 7.4) (EDTA/PBS) containing 0.5 mM EDTA and 150 mM NaCl, and then suspended in 0.5 ml of a FACS buffer. Next, biotinylated PNA lectin was added as a primary antibody at 5 μ g/ml, and then left to stand on ice for 30 minutes. After excessive biotinylated PNA lectin was washed off using a FACS buffer (Becton Dickinson), FITC-labeled streptavidin was added as a secondary antibody at a concentration of 10 μ g/ml, and then similarly allowed to react on ice for 20 minutes. After washing with a FACS buffer, an aggregated cell mass was removed by filtration through nylon mesh. The cells were suspended in a FACS buffer at a concentration of 10^5 cells/ml. The suspension was stored on ice until sorting.

For cell screening, flow cytometry was used (Fig. 14) instead of using the method utilizing MACS as described in Example 3. Flow cytometry was carried out using FACS Vantage (produced by Becton Dickinson). Following optical axis adjustment and channel sterilization, the cells prepared as described above were sorted according to the manuals. A screening window was provided for a PNA lectin-positive cell fraction to be approximately around 0.1%. 1.4×10^6 cells were sorted, and then 1,187 PNA-lectin-positive cell fractions were obtained. In tubes for collection, lactose, the hapten sugar of PNA, with a concentration of 20 μ M, had been previously added to FACS buffer. Positive cells were inoculated on a 24-well dish, and then cultured in RPMI1640 containing 10% FBS in the presence of 5% CO₂. Lactose was used for releasing PNA lectin from PNA lectin-positive cells, because PNA lectin bound to the cells may provide a cytotoxic effect. 2 weeks later, the cells were stained with PNA lectin, and then the proportion of PNA-positive cells was examined (Fig. 15, 1st PNA(+)).

The second sorting was carried out by a method similar to that of the first sorting by providing a screening window for a PNA lectin-positive cell fraction to

be approximately around 0.25% (2,352 cell fractions/ 6.3×10^5 cells). After 2 weeks of culture, the cells were stained with PNA lectin, and then the percentage of PNA-positive cells was examined (Fig. 15, 2nd PNA(+)).

5 (3) Cloning of PNA lectin-positive cells

The PNA-lectin-positive cells collected in the second sorting were suspended in 10 ml of RPMI1640 containing 10% FBS. The suspension was inoculated in a flat-bottomed 96-well plate with 200 μ l of the suspension in each of 50 wells, and then cultured. At the time when colonies within the wells could be visually confirmed, wells having a concentration of 1 colony per well were selected and then collected with EDTA/PBS, followed by subculture in a 24-well plate. 19 out of 50 wells had 1 colony per well. At the time when the culture in the 24-well plate became confluent, binding of each cell clone to PNA lectin was examined. Among 19 wells, the cells in 13 wells were strongly stained with PNA, and a plurality of PNA lectin-positive cell clones were obtained. One of these clones, clone 23, is shown in Fig. 15 (Clone 23). The upper row of Fig. 15 shows fluorescence intensity before sorting, that after the 1st sorting, and that after the 2nd sorting. The lower row in Fig. 15 shows fluorescence intensity of clone 23 obtained after the 2nd sorting. As shown in the graph at the lower right in Fig. 15, FITC fluorescence intensity was 3.2 in the case of the CHO cells, the parent line, whereas in the case of clone 23, it was 268.5, which was approximately 100 times greater than the former fluorescence intensity.

(4) Examination of FLAG tag expression of PNA lectin-positive cell clone 12

For one of the clones obtained in (3) above (clone 12), whether or not mutated VIP36, the product of the foreign gene, was expressed was examined using anti-FLAG antibody. Upon constructing a mutated VIP36 gene, it was designed such that a FLAG tag sequence was added to the N-terminus. Hence, the expression of altered VIP36 can be examined by staining it with the

anti-FLAG antibody. Thus, PNA lectin-positive cell clone 12 cultured to be 70% confluent was harvested with EDTA/PBS and then allowed to react with both the anti-FLAG antibody (3.3 $\mu\text{g/ml}$) and biotinylated PNA (3.3 $\mu\text{g/ml}$) simultaneously on ice for 30 minutes. After washing with a FACS buffer, the clone was further
5 allowed to react with FITC-labeled anti-mouse IgG (5 $\mu\text{g/ml}$) and PE (phycoerythrin)-labeled streptavidin (1 $\mu\text{g/ml}$) on ice for 20 minutes. Fluorescence intensity of the cells was analyzed using an analyzer (FACSCalibur) (Fig. 16). In Fig. 16, "none" represents the result when nothing corresponding to a primary antibody had been added. "Control Ab" represents the result when an
10 anti-rat IgG antibody known not to bind to CHO cells had been allowed to react as a primary antibody to stain the cells, "PNA" represents the result when the biotinylated PNA lectin had been allowed to react as a primary antibody to stain the cells, and "anti-FLAG Ab" represents the result when the anti-FLAG antibody had been allowed to react as a primary antibody to stain the cells. Although the
15 expression level in clone 12 cells was low, clone 12 cells were clearly FLAG-positive.

(5) Analysis of mutated VIP36 gene expressed on PNA-positive clones

mRNA was extracted from various PNA lectin-positive cell clones using a
20 μ MACS system (Daiichi Pure Chemicals). The cells cultured to be 50% to 60% confluent in four 10-cm dishes were collected with trypsin/EDTA, and then suspended in a lysis/binding buffer (Daiichi Pure Chemicals, attached within a kit) so as to disrupt the cells. mRNA was annealed to oligo (dT) microbeads (Daiichi Pure Chemicals), and then applied to a MACS column. The column was
25 further washed with a lysis/binding buffer and a washing buffer (Daiichi Pure Chemicals, attached within a kit), and then an elution buffer (Daiichi Pure Chemicals, attached within a kit) was added so as to elute mRNA from the column. 6.3 mg of mRNA was obtained from 1.1×10^7 cells.

1 mg of mRNA was dissolved in 20 μl of Milli-Q water, and then to which

1 μ g of oligo(dT) was added. The solution was heated at 70°C for 10 minutes,
and then chilled on ice. 2 μ l of 10 mM dNTP, 4 μ l of 0.1 M DTT, 2 μ l of 40
U/ μ l RNase inhibitor, and 8 μ l of a 5 $\times$ first strand buffer were added. After the
solution was warmed at 42°C, 2 μ l of Superscript II was added, followed by 50
5 minutes of reaction at 42°C. This reaction solution was used as a template for
the next PCR reaction. PCR reaction was performed using the VIP36 gene 5'
terminal and 3' terminal oligo DNA primers (Example 1, VIPran1, 5) used upon
library construction. Reaction was conducted using KOD-plus DNA polymerase
(TOYOBO) under conditions of 35 cycles of denaturation at 94°C for 15 seconds,
10 annealing at 51°C for 30 seconds, and elongation at 68°C for 1 minute. By
agarose electrophoresis, a band corresponding to approximately 960 nucleotide
pairs was confirmed and the thus obtained DNA fragment was collected. The
collected gene was inserted into the *Sma* I site of pBluescript II SK, replicated
within *Escherichia coli*, and then extracted. Thus, the nucleotide sequence was
15 determined. As a result of analyzing a gene encoding the altered VIP36 that had
been introduced into clone 12, the nucleotide sequence encoding the mutatedd
loop was found to be 5'-GACCCTGATTCTAATGGTGGTTCTTTT-3' (SEQ ID
NO: 16) and predicted amino acid sequence was
Asp-Pro-Asp-Ser-Asn-Gly-Gly-Ser-Phe (SEQ ID NO: 17).

20

All publications, patents, and patent applications cited herein are
incorporated herein by reference in their entirety.

INDUSTRIAL APPLICABILITY

25

According to the present invention, a method for modifying a
carbohydrate moiety and cells expressing glycoproteins having a modified
carbohydrate moiety are provided. Such a carbohydrate moiety
(oligosaccharide) having a specific sugar structure and glycoproteins having such
a carbohydrate moiety are required in the fields of medicine. Since such

oligosaccharides and proteins can be produced conveniently and rapidly, the method for modifying a carbohydrate moiety and the cell expressing such glycoproteins having a modified carbohydrate moiety according to the present invention are useful.

- 5 Furthermore, the present invention makes it possible to construct a oligosaccharide library comprising cells expressing various oligosaccharides, generate unknown oligosaccharides, and examine the usefulness thereof.

SEQUENCE FREE TEXT

- 10 SEQ ID NOS: 5 to 16: synthetic oligonucleotide (N=A, T, G, or C)
SEQ ID NO: 17: synthetic peptide

CLAIMS

1. A method for modifying a carbohydrate moiety of a glycoprotein in a cell in culture, which comprises altering at least one amino acid in a carbohydrate recognition domain of a cargo receptor in a cell, expressing the cargo receptor in the cell, and expressing a glycoprotein with a modified carbohydrate moiety in the cell, wherein the cargo receptor is VIP36 and/or ERGIC-53.
2. The method according to claim 1, wherein the glycoprotein is a membrane-bound protein or a secretory protein.
3. A method for producing an oligosaccharide, which comprises altering at least one amino acid in a carbohydrate recognition domain of a cargo receptor in a cell in culture, expressing the cargo receptor in the cell, expressing a glycoprotein with a modified carbohydrate moiety in the cell, and cleaving an oligosaccharide from the glycoprotein, wherein the cargo receptor is VIP36 and/or ERGIC-53.
4. The method according to claim 3, wherein the oligosaccharide is selected from the group consisting of D-gal, D-Man, D-Glc, D-GlcNAc, L-Fuc, SA, and D-GalNAc.

5. A method for preparing a cell expressing a glycoprotein with a modified carbohydrate moiety, which comprises altering at least one amino acid in a carbohydrate recognition domain of a cargo receptor in a cell in culture, expressing the cargo receptor in the cell, and selecting the cell expressing a glycoprotein with a modified carbohydrate moiety, wherein the cargo receptor is VIP36 and/or ERGIC-53

6. The method according to claim 5, wherein the glycoprotein is a membrane-bound protein or a secretory protein.

7. The method according to claim 5 or 6, which further comprises introducing the gene of a desired protein into a cell in culture, and obtaining a cell expressing a desired glycoprotein having a modified carbohydrate moiety.

8. A cell expressing a glycoprotein with a modified carbohydrate moiety, which is prepared by the method according to any one of claims 5 to 7, and wherein said cell is in culture.

9. A method for producing a glycoprotein with a modified carbohydrate moiety, which comprises culturing the cell according to claim 8 and collecting a glycoprotein with a modified carbohydrate moiety from the obtained culture.

10. A method for constructing a cell library comprising a plurality of cells in culture, each expressing a glycoprotein with a modified carbohydrate moiety, which comprises introducing random mutations into a nucleotide sequence of carbohydrate recognition domain of a cargo receptor gene, introducing the cargo receptor gene having the above random mutations into each of a plurality of cells, expressing the cargo receptor gene in each of the plurality of

cells, and expressing a glycoprotein with a modified carbohydrate moiety in each of the plurality of cells, wherein the cargo receptor is VIP36 and/or ERGIC-53.

11. A method for screening for a test substance interacting with a glycoprotein or an oligosaccharide, which comprises: contacting, in culture, the cell expressing the glycoprotein with a modified carbohydrate moiety according to claim 8 or the cell library that is constructed by the method according to claim 10 with a test substance, and determining the interaction between the glycoprotein or the carbohydrate moiety with the test substance.

SEQUENCE LISTING

<110> YAMAMOTO, Kazuo
Sumitomo Corporation

<120> Carbohydrate library constructed by Gene Alteration of Cargo
Receptors

<130> PH-1716PCT

<140>

<141>

<150> JP 2002-238559

<151> 2002-08-19

<160> 17

<170> PatentIn Ver. 2.0

<210> 1

<211> 2768

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (22)..(1554)

<220>

<221> sig_peptide

<222> (22)..(112)

<400> 1

ggtcgcgttc cagaatccaa g atg gcg gga tcc agg caa agg ggt ctc cgg 51
Met Ala Gly Ser Arg Gln Arg Gly Leu Arg
1 5 10

gcc aga gtt cgg ccg ctg ttc tgc gcc ttg ctg ctg tca ctc ggt cgc 99
Ala Arg Val Arg Pro Leu Phe Cys Ala Leu Leu Leu Ser Leu Gly Arg
15 20 25

ttc gtc cgg ggc gac ggc gtg gga gga gac ccc gcg gtc gcg ttg cca 147
Phe Val Arg Gly Asp Gly Val Gly Gly Asp Pro Ala Val Ala Leu Pro

30

35

40

cat cgc cgt ttc gag tac aaa tac agc ttc aag ggg ccg cac ctg gtg 195
 His Arg Arg Phe Glu Tyr Lys Tyr Ser Phe Lys Gly Pro His Leu Val
 45 50 55

cag agc gac ggg acc gtg ccc ttc tgg gcc cac gcg ggg aat gct att 243
 Gln Ser Asp Gly Thr Val Pro Phe Trp Ala His Ala Gly Asn Ala Ile
 60 65 70

cca agt tca gat caa att cga gta gca cca tct tta aaa agc caa aga 291
 Pro Ser Ser Asp Gln Ile Arg Val Ala Pro Ser Leu Lys Ser Gln Arg
 75 80 85 90

ggc tca gtg tgg aca aag aca aaa gcg gcc ttt gag aac tgg gaa gtt 339
 Gly Ser Val Trp Thr Lys Thr Lys Ala Ala Phe Glu Asn Trp Glu Val
 95 100 105

gag gtg aca ttt cga gtg act gga aga ggt cga att gga gct gat ggc 387
 Glu Val Thr Phe Arg Val Thr Gly Arg Gly Arg Ile Gly Ala Asp Gly
 110 115 120

cta gca att tgg tat gca gaa aat caa ggc ttg gag ggc cct gtg ttt 435
 Leu Ala Ile Trp Tyr Ala Glu Asn Gln Gly Leu Glu Gly Pro Val Phe
 125 130 135

gga tca gct gat ctg tgg aat ggt gtt gga ata ttt ttt gat act ttt 483
 Gly Ser Ala Asp Leu Trp Asn Gly Val Gly Ile Phe Phe Asp Thr Phe
 140 145 150

gac aat gat gga aag aaa aat aat cct gct ata gta att ata ggc aac 531
 Asp Asn Asp Gly Lys Lys Asn Asn Pro Ala Ile Val Ile Ile Gly Asn
 155 160 165 170

aat gga caa atc cat tat gac cat caa aat gac ggg gct agt caa gct 579
 Asn Gly Gln Ile His Tyr Asp His Gln Asn Asp Gly Ala Ser Gln Ala
 175 180 185

ttg gca agt tgc cag agg gac ttc cgc aac aaa ccc tat cct gtc cga 627
 Leu Ala Ser Cys Gln Arg Asp Phe Arg Asn Lys Pro Tyr Pro Val Arg
 190 195 200

gca aag att acc tat tac cag aac aca ctg aca gta atg atc aat aat 675
 Ala Lys Ile Thr Tyr Tyr Gln Asn Thr Leu Thr Val Met Ile Asn Asn
 205 210 215

ggc ttt aca cca gat aaa aat gat tat gaa ttt tgt gcc aaa gtg gaa	723
Gly Phe Thr Pro Asp Lys Asn Asp Tyr Glu Phe Cys Ala Lys Val Glu	
220 225 230	
aat atg att atc cct gca caa ggg cat ttt gga ata tct gct gca act	771
Asn Met Ile Ile Pro Ala Gln Gly His Phe Gly Ile Ser Ala Ala Thr	
235 240 245 250	
gga ggt ctt gca gat gac cat gat gtc ctt tct ttt ctg act ttc cag	819
Gly Gly Leu Ala Asp Asp His Asp Val Leu Ser Phe Leu Thr Phe Gln	
255 260 265	
ttg act gaa cct gga aaa gag ccg ccc aca cca gat aaa gaa att tcg	867
Leu Thr Glu Pro Gly Lys Glu Pro Pro Thr Pro Asp Lys Glu Ile Ser	
270 275 280	
gaa aag gaa aaa gaa aag tat cag gag gaa ttt gag cac ttt caa caa	915
Glu Lys Glu Lys Glu Lys Tyr Gln Glu Glu Phe Glu His Phe Gln Gln	
285 290 295	
gaa ttg gat aaa aaa aaa gag gaa ttc cag aag ggc cac ccc gac ctc	963
Glu Leu Asp Lys Lys Lys Glu Glu Phe Gln Lys Gly His Pro Asp Leu	
300 305 310	
caa ggg cag cct gcg gag gaa ata ttt gag agt gta gga gat cga gag	1011
Gln Gly Gln Pro Ala Glu Glu Ile Phe Glu Ser Val Gly Asp Arg Glu	
315 320 325 330	
cta aga caa gtc ttt gaa gga cag aat cgt att cat ctt gaa atc aag	1059
Leu Arg Gln Val Phe Glu Gly Gln Asn Arg Ile His Leu Glu Ile Lys	
335 340 345	
cag ctg aac cgg cag tta gat atg att ctt gat gaa cag aga aga tat	1107
Gln Leu Asn Arg Gln Leu Asp Met Ile Leu Asp Glu Gln Arg Arg Tyr	
350 355 360	
gtc tct tcc tta aca gag gaa atc tct aaa aga gga gca gga atg cct	1155
Val Ser Ser Leu Thr Glu Glu Ile Ser Lys Arg Gly Ala Gly Met Pro	
365 370 375	
ggg cag cat ggg cag att act caa caa gaa ctg gat act gtt gtg aaa	1203
Gly Gln His Gly Gln Ile Thr Gln Gln Glu Leu Asp Thr Val Val Lys	
380 385 390	

act cag cat gag att ctg aga caa gta aat gaa atg aaa aat tcc atg	1251
Thr Gln His Glu Ile Leu Arg Gln Val Asn Glu Met Lys Asn Ser Met	
395 400 405 410	
agt gaa acc gtc aga ctg gtc agt gga atg cag cac cct ggc tct gct	1299
Ser Glu Thr Val Arg Leu Val Ser Gly Met Gln His Pro Gly Ser Ala	
415 420 425	
gga ggc gtc tat gag aca aca cag cac ttc att gac atc aaa gag cac	1347
Gly Gly Val Tyr Glu Thr Thr Gln His Phe Ile Asp Ile Lys Glu His	
430 435 440	
ctg cac ata gta aag agg gac ata gat aac tta gtg cag cga aat atg	1395
Leu His Ile Val Lys Arg Asp Ile Asp Asn Leu Val Gln Arg Asn Met	
445 450 455	
cca tca aat gaa aag ccg aaa tgc cca gaa cta cca cca ttt cca tca	1443
Pro Ser Asn Glu Lys Pro Lys Cys Pro Glu Leu Pro Pro Phe Pro Ser	
460 465 470	
tgt ttg tct acg gtc cac ttc att ata ttt gtt gtg gtg caa act gta	1491
Cys Leu Ser Thr Val His Phe Ile Ile Phe Val Val Val Gln Thr Val	
475 480 485 490	
tta ttc att ggt tat atc atg tat agg tct cag caa gaa gca gct gcc	1539
Leu Phe Ile Gly Tyr Ile Met Tyr Arg Ser Gln Gln Glu Ala Ala Ala	
495 500 505	
aaa aaa ttc ttt tga ctaccatttt cctgtgtact tcattctattt gtgtacaaaa	1594
Lys Lys Phe Phe	
510	
tgagtcgttt tgagggaatt taagtattta aattgcttca tagtctaaat tattaatttt	1654
cttaataaaa taactgttta aacattgatt tgcagttaag aataaacctt aaagcaaaga	1714
caaccacatt ttaatttggt cacagtatgt aaatctgtct aaatttcagt gaatttctgg	1774
tcagtatgat gcagcctctg agcagaatat tgaccagtaa gagggtaaataa aaagtggggg	1834
caaccctgga tatgaatggt accccctaag tctccaatat tgcaggtttc cctgtataac	1894
gtaaacacac ttgcctcat gcctcccaga atatgaggtc taattaagaa gtccatcagg	1954
tttattttgt aaccaaagtc ttttttagag gtcagacttc ctaatcaaag gcctgggcct	2014

gcagtcacct tcattttaat gcaacttcct ttgaaatcaa agaataatgt gtctgagagc 2074
 ttttaaggatc tggtaataga cttcaaaatg ttaagtgaat tttttttttc ctctatttat 2134
 caatgatata tttcactttt aaaggaaatt ttagaggaaa attaataagct gcttttttgc 2194
 ctaaaaaaac ttgtgggtgg aaatattcct ctgagaatgg cttttatagg tattttgcct 2254
 ggtaatgtat tcattcatga ttgcccatat tcttgaatgt ttcttcattc caatggggtc 2314
 aggtcaatat tatgaaaata atttttatat ttatatattgt aactaagaat ttatttctcc 2374
 ctttactaca cgatgtaaat tcacgtcaaa ttgatgac tgaggattta aattcacaaa 2434
 acctgccact acattctggt ttacattagt tacttcatgc tggctggggg tagtgaccat 2494
 ttgcatactc ttttaaatca aggaggctgt agtagaggca gttttaagat tcttgaaggc 2554
 aaaatttgaa aaacagtga tacttcta atgtttcctt tagtgccaga actaagacat 2614
 tgtgaagcac ttgttagtaa acttaacctt gaaatgtcag actggaagga gtttttatgt 2674
 ctttgtgcat acttctgggt attacagaaa cagtctgtaa ataacatttt aagatgcaaa 2734
 ttttaattctg ttcacagctg atttatactg attt 2768

<210> 2
 <211> 510
 <212> PRT
 <213> Homo sapiens

<400> 2
 Met Ala Gly Ser Arg Gln Arg Gly Leu Arg Ala Arg Val Arg Pro Leu
 1 5 10 15
 Phe Cys Ala Leu Leu Leu Ser Leu Gly Arg Phe Val Arg Gly Asp Gly
 20 25 30
 Val Gly Gly Asp Pro Ala Val Ala Leu Pro His Arg Arg Phe Glu Tyr
 35 40 45
 Lys Tyr Ser Phe Lys Gly Pro His Leu Val Gln Ser Asp Gly Thr Val
 50 55 60

Pro Phe Trp Ala His Ala Gly Asn Ala Ile Pro Ser Ser Asp Gln Ile
65 70 75 80

Arg Val Ala Pro Ser Leu Lys Ser Gln Arg Gly Ser Val Trp Thr Lys
85 90 95

Thr Lys Ala Ala Phe Glu Asn Trp Glu Val Glu Val Thr Phe Arg Val
100 105 110

Thr Gly Arg Gly Arg Ile Gly Ala Asp Gly Leu Ala Ile Trp Tyr Ala
115 120 125

Glu Asn Gln Gly Leu Glu Gly Pro Val Phe Gly Ser Ala Asp Leu Trp
130 135 140

Asn Gly Val Gly Ile Phe Phe Asp Thr Phe Asp Asn Asp Gly Lys Lys
145 150 155 160

Asn Asn Pro Ala Ile Val Ile Ile Gly Asn Asn Gly Gln Ile His Tyr
165 170 175

Asp His Gln Asn Asp Gly Ala Ser Gln Ala Leu Ala Ser Cys Gln Arg
180 185 190

Asp Phe Arg Asn Lys Pro Tyr Pro Val Arg Ala Lys Ile Thr Tyr Tyr
195 200 205

Gln Asn Thr Leu Thr Val Met Ile Asn Asn Gly Phe Thr Pro Asp Lys
210 215 220

Asn Asp Tyr Glu Phe Cys Ala Lys Val Glu Asn Met Ile Ile Pro Ala
225 230 235 240

Gln Gly His Phe Gly Ile Ser Ala Ala Thr Gly Gly Leu Ala Asp Asp
245 250 255

His Asp Val Leu Ser Phe Leu Thr Phe Gln Leu Thr Glu Pro Gly Lys
260 265 270

Glu Pro Pro Thr Pro Asp Lys Glu Ile Ser Glu Lys Glu Lys Glu Lys
275 280 285

Tyr Gln Glu Glu Phe Glu His Phe Gln Gln Glu Leu Asp Lys Lys Lys
290 295 300

Glu Glu Phe Gln Lys Gly His Pro Asp Leu Gln Gly Gln Pro Ala Glu
 305 310 315 320
 Glu Ile Phe Glu Ser Val Gly Asp Arg Glu Leu Arg Gln Val Phe Glu
 325 330 335
 Gly Gln Asn Arg Ile His Leu Glu Ile Lys Gln Leu Asn Arg Gln Leu
 340 345 350
 Asp Met Ile Leu Asp Glu Gln Arg Arg Tyr Val Ser Ser Leu Thr Glu
 355 360 365
 Glu Ile Ser Lys Arg Gly Ala Gly Met Pro Gly Gln His Gly Gln Ile
 370 375 380
 Thr Gln Gln Glu Leu Asp Thr Val Val Lys Thr Gln His Glu Ile Leu
 385 390 395 400
 Arg Gln Val Asn Glu Met Lys Asn Ser Met Ser Glu Thr Val Arg Leu
 405 410 415
 Val Ser Gly Met Gln His Pro Gly Ser Ala Gly Gly Val Tyr Glu Thr
 420 425 430
 Thr Gln His Phe Ile Asp Ile Lys Glu His Leu His Ile Val Lys Arg
 435 440 445
 Asp Ile Asp Asn Leu Val Gln Arg Asn Met Pro Ser Asn Glu Lys Pro
 450 455 460
 Lys Cys Pro Glu Leu Pro Pro Phe Pro Ser Cys Leu Ser Thr Val His
 465 470 475 480
 Phe Ile Ile Phe Val Val Val Gln Thr Val Leu Phe Ile Gly Tyr Ile
 485 490 495
 Met Tyr Arg Ser Gln Gln Glu Ala Ala Ala Lys Lys Phe Phe
 500 505 510

<210> 3

<211> 1407

<212> DNA

<213> Homo sapiens

<220>

<221> CDS
 <222> (1).. (1071)

<220>
 <221> sig_peptide
 <222> (1).. (134)

<400> 3

atg gcg gcg gaa ggc tgg att tgg cgt tgg ggc tgg ggc cgg cgg tgc	48
Met Ala Ala Glu Gly Trp Ile Trp Arg Trp Gly Trp Gly Arg Arg Cys	
1 5 10 15	
ctg gga agg cct ggg ctt ctc ggc ccc ggc cct ggc ccc act aca cct	96
Leu Gly Arg Pro Gly Leu Leu Gly Pro Gly Pro Gly Pro Thr Thr Pro	
20 25 30	
ctc ttt ctt ctt ttg ttg ttg ggg tct gtg act gcg gat ata act gac	144
Leu Phe Leu Leu Leu Leu Leu Gly Ser Val Thr Ala Asp Ile Thr Asp	
35 40 45	
ggc aac agt gaa cat ctc aag cgg gag cat tcg ctc att aag ccc tac	192
Gly Asn Ser Glu His Leu Lys Arg Glu His Ser Leu Ile Lys Pro Tyr	
50 55 60	
caa ggg gtc ggt tcc agc tct atg ccc ctc tgg gac ttc cag ggc agc	240
Gln Gly Val Gly Ser Ser Ser Met Pro Leu Trp Asp Phe Gln Gly Ser	
65 70 75 80	
act atg ctc acg agc cag tac gta cgt ctg acc cct gac gag cgc agc	288
Thr Met Leu Thr Ser Gln Tyr Val Arg Leu Thr Pro Asp Glu Arg Ser	
85 90 95	
aaa gag ggc tct atc tgg aac cac cag ccg tgc ttc ctc aaa gac tgg	336
Lys Glu Gly Ser Ile Trp Asn His Gln Pro Cys Phe Leu Lys Asp Trp	
100 105 110	
gaa atg cac gtc cac ttc aaa gtc cac ggc aca ggg aag aag aac ctc	384
Glu Met His Val His Phe Lys Val His Gly Thr Gly Lys Lys Asn Leu	
115 120 125	
cat gga gac ggc atc gcc ttg tgg tac acc cgg gac cgc ctc gtg cca	432
His Gly Asp Gly Ile Ala Leu Trp Tyr Thr Arg Asp Arg Leu Val Pro	
130 135 140	
ggg cct gtg ttt gga agc aaa gat aac ttc cac ggc tta gcc atc ttc	480

325

330

335

tgc gcc gtg gtg ggg gcc gtg gtg ttc cag aag cgg cag gag cgg aac 1056
 Cys Ala Val Val Gly Ala Val Val Phe Gln Lys Arg Gln Glu Arg Asn
 340 345 350

aag cgc ttc tac tga gtggcgccctc cggcgggggcc tgtccctggg cccaggagcc 1111
 Lys Arg Phe Tyr
 355

aatgtgaact ttttttttta ccgggattat aaaagaacaa caagatgacc ttattttctta 1171

actgtttcaa ataaatgatt aaagtatttt catacatttt gcttcttgcc cagcaggagc 1231

aggtggcaga gccgaggctt aggggtctggc accccccaca gctggagacg gaggtctctcc 1291

tggggctggt gtctcaggag caggggtctg tgtctacaga tgggctgtgg cccctgcagg 1351

cagctgttga aactggagg gtcccccgga ccacactggg gtgggtcctt gaggac 1407

<210> 4

<211> 356

<212> PRT

<213> Homo sapiens

<400> 4

Met Ala Ala Glu Gly Trp Ile Trp Arg Trp Gly Trp Gly Arg Arg Cys
 1 5 10 15

Leu Gly Arg Pro Gly Leu Leu Gly Pro Gly Pro Gly Pro Thr Thr Pro
 20 25 30

Leu Phe Leu Leu Leu Leu Leu Gly Ser Val Thr Ala Asp Ile Thr Asp
 35 40 45

Gly Asn Ser Glu His Leu Lys Arg Glu His Ser Leu Ile Lys Pro Tyr
 50 55 60

Gln Gly Val Gly Ser Ser Ser Met Pro Leu Trp Asp Phe Gln Gly Ser
 65 70 75 80

Thr Met Leu Thr Ser Gln Tyr Val Arg Leu Thr Pro Asp Glu Arg Ser
 85 90 95

Lys Glu Gly Ser Ile Trp Asn His Gln Pro Cys Phe Leu Lys Asp Trp

100	105	110
Glu Met His Val His Phe Lys Val His Gly Thr Gly Lys Lys Asn Leu		
115	120	125
His Gly Asp Gly Ile Ala Leu Trp Tyr Thr Arg Asp Arg Leu Val Pro		
130	135	140
Gly Pro Val Phe Gly Ser Lys Asp Asn Phe His Gly Leu Ala Ile Phe		
145	150	155
Leu Asp Thr Tyr Pro Asn Asp Glu Thr Thr Glu Arg Val Phe Pro Tyr		
165	170	175
Ile Ser Val Met Val Asn Asn Gly Ser Leu Ser Tyr Asp His Ser Lys		
180	185	190
Asp Gly Arg Trp Thr Glu Leu Ala Gly Cys Thr Ala Asp Phe Arg Asn		
195	200	205
Arg Asp His Asp Thr Phe Leu Ala Val Arg Tyr Ser Arg Gly Arg Leu		
210	215	220
Thr Val Met Thr Asp Leu Glu Asp Lys Asn Glu Trp Lys Asn Cys Ile		
225	230	235
Asp Ile Thr Gly Val Arg Leu Pro Thr Gly Tyr Tyr Phe Gly Ala Ser		
245	250	255
Ala Gly Thr Gly Asp Leu Ser Asp Asn His Asp Ile Ile Ser Met Lys		
260	265	270
Leu Phe Gln Leu Met Val Glu His Thr Pro Asp Glu Glu Ser Ile Asp		
275	280	285
Trp Thr Lys Ile Glu Pro Ser Val Asn Phe Leu Lys Ser Pro Lys Asp		
290	295	300
Asn Val Asp Asp Pro Thr Gly Asn Phe Arg Ser Gly Pro Leu Thr Gly		
305	310	315
Trp Arg Val Phe Leu Leu Leu Cys Ala Leu Leu Gly Ile Val Val		
325	330	335
Cys Ala Val Val Gly Ala Val Val Phe Gln Lys Arg Gln Glu Arg Asn		

Lys Arg Phe Tyr
355

<210> 5
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 5
gcatgtcgac ataactgacg gcaacagtg

29

<210> 6
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 6
gagctctaga aagatggcta agccgtggaa

30

<210> 7
<211> 53
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic
oligonucleotide

<220>
<223> N=A, T, C or G

<400> 7
cgtgctctag acnnknnknn kaatnnknnk nnknnkgagc gcgtgttccc gta

53

<210> 8

<211> 30
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 8

atcgtcttaa gcactcagta gaagcgcttg

30

<210> 9

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 9

gactacaaag acgatgacga caag

24

<210> 10

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 10

ctagaagtcc ttaagagtcg ggcc

24

<210> 11

<211> 16

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 11

cgactcttaa ggactt

16

<210> 12

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 12

gtacgtcgac ggcgtgggag gag

23

<210> 13

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 13

cgtatctaga aatattccaa caccattcca

30

<210> 14

<211> 58

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<220>

<223> N=A, T, C or G

<400> 14

cgtatctaga tnnknnknnk aatnnknnkn nknnkaataa tctgtctata gtaattat 58

<210> 15

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 15

cgtacttaag tggtagtcaa aagaattttt tg

32

<210> 16

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
oligonucleotide

<400> 16

gaccctgatt ctaatggtgg ttctttt

27

<210> 17

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
peptide

<400> 17

Asp Pro Asp Ser Asn Gly Gly Ser Phe

1

5